



Published in final edited form as:

Exp Eye Res. 2022 September ; 222: 109170. doi:10.1016/j.exer.2022.109170.

Cell culture models to study retinal pigment epithelium-related pathogenesis in age-related macular degeneration

Kapil Bharti¹, Anneke I. den Hollander^{2,3}, Aparna Lakkaraju⁴, Debashish Sinha^{5,6}, David Williams⁷, Silvia C. Finnemann⁸, Catherine Bowes Rickman⁹, Goldis Malek¹⁰, Patricia A. D'Amore¹¹

¹Ocular and Stem Cell Translational Research Section, National Eye Institute, NIH, Bethesda, MD

²Department of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands

³AbbVie, Genomics Research Center, Cambridge, MA

⁴Department of Ophthalmology, School of Medicine, University of California, San Francisco

⁵Department of Ophthalmology, Cell Biology and Developmental Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

⁶Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

⁷Stein Eye Institute, Departments of Ophthalmology and Neurobiology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA

⁸Center of Cancer, Genetic Diseases, and Gene Regulation, Department of Biological Sciences, Fordham University, Bronx, NY

⁹Duke Eye Center, Department of Ophthalmology, Duke University School of Medicine, Durham, NC, Department of Cell Biology, Duke University School of Medicine, Durham, NC

¹⁰Duke Eye Center, Department of Ophthalmology, Duke University School of Medicine, Durham, NC, Department of Pathology, Duke University School of Medicine, Durham, NC

¹¹Mass Eye and Ear, Departments of Ophthalmology and Pathology, Harvard Medical School, Boston, MA

Abstract

Age-related macular degeneration (AMD) is a disease that affects the macula – the central part of the retina. It is a leading cause of irreversible vision loss in the elderly. AMD onset is marked by the presence of lipid- and protein-rich extracellular deposits around the retinal pigment epithelium (RPE), a monolayer of polarized, pigmented epithelial cells located between the photoreceptors and the choroidal blood supply. Progression of AMD to the late nonexudative “dry” stage

Address for correspondence: Kapil Bharti: kapil.bharti@nih.gov.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Competing interests

Anneke is currently an employee of AbbVie.

of AMD, also called geographic atrophy, is linked to progressive loss of areas of the RPE, photoreceptors, and underlying choriocapillaris leading to a severe decline in patients' vision. Differential susceptibility of macular RPE in AMD and the lack of an anatomical macula in most lab animal models has promoted the use of *in vitro* models of the RPE. In addition, the need for high throughput platforms to test potential therapies has driven the creation and characterization of *in vitro* model systems that recapitulate morphologic and functional abnormalities associated with human AMD. These models range from spontaneously formed cell line ARPE19, immortalized cell lines such as hTERT-RPE1, RPE-J, and D407, to primary human (fetal or adult) or animal (mouse and pig) RPE cells, and embryonic and induced pluripotent stem cell (iPSC) derived RPE. Hallmark RPE phenotypes, such as cobblestone morphology, pigmentation, and polarization, vary significantly between different models limiting their usability for investigating different aspects of AMD biology. Here the AMD Disease Models task group of the Ryan Initiative for Macular Research (RIMR) provides a summary of several currently used *in vitro* RPE models, historical aspects of their development, RPE phenotypes that are attainable in these models, their ability to model different aspects of AMD pathophysiology, and pros/cons for their use in the RPE and AMD fields. In addition, due to the burgeoning use of iPSC derived RPE cells, the critical need for developing standards for differentiating and rigorously characterizing RPE cell appearance, morphology, and function are discussed.

Keywords

retinal pigment epithelium; ARPE19; primary cells; iPSC-RPE; Organ-on-a-Chip; complement system

INTRODUCTION

Age-related macular degeneration (AMD) affects over 30 million individuals world-wide, and these numbers are expected to double by 2050 (Rein et al., 2009). AMD affects the macula, the central part of the retina that is responsible for central and sharp vision (Swaroop et al., 2009). Clinically, AMD is classified into two advanced stages, nonexudative 'dry' AMD or geographic atrophy, characterized by degeneration of the retinal pigment epithelium (RPE) and photoreceptors in the macula, and exudative 'wet' AMD or choroidal neovascularization (CNV), characterized by hyperproliferation and migration of choroidal capillaries into the sub-RPE, subretinal, or the intraretinal space (Swaroop et al., 2009). AMD onset and progression have been linked to genetic and environmental risk-factors including age and lifestyle (e.g. diet and smoking); and genetic factors, which include risk alleles in genes (Swaroop et al., 2009) identified through genome-wide association studies (GWAS) (Fritsche et al., 2016). Several features of AMD pathophysiology make this one of the hardest diseases to model *in vitro* and *in vivo*. For instance, most routinely used lab animals do not have a macula; animal cells cannot replicate human genetic risk alleles associated with AMD; diet and aging are not easy to mimic in animals or cell culture; and specifically macular cells have not been successfully cultured *in vitro*. However, a growing body of evidence suggests that reliable models can be developed/utilized to study certain aspects of AMD pathogenesis.

There has been significant interest in the biology of the RPE, a pigmented monolayer of post-mitotic cells located between the photoreceptors and the choroidal blood supply (Bharti et al., 2006). Multiple studies have suggested the RPE monolayer as the primary site of disease initiation (Wang et al., 2018). Accordingly, a majority of *in vitro* models focus on RPE cells, fidelity of the cell systems to the *in vivo* biology of RPE, and how it relates to AMD pathogenesis.

The AMD Disease Models task group of the Ryan Initiative for Macular Research (RIMR) aimed to provide direction on currently available and upcoming *in vitro* models used for better understanding of RPE cell biology and AMD pathogenesis related to RPE dysfunction. Between February and April 2021, the task group convened in four virtual sessions. The task group discussed the following models: immortalized RPE cell lines, primary RPE cells obtained from animals (mice and pigs) and donor human eyes (adult and fetal), as well as RPE cells differentiated from induced pluripotent stem cells (iPSCs). This review provides a summary of the discussions held during the RIMR AMD Disease Models task group meetings about usability, strengths, and limitations of these models for AMD research. This review also provides guidance on assays to compare RPE models across labs and quantitative readouts of RPE cell health under physiological stressors related to AMD pathogenesis.

RPE CELL LINES

Cell lines spontaneously formed from primary cultures (e.g. the ARPE19 cell line, Dunn et al., 1996) or by introduction of one of a number of immortalizing genes (hTERT-RPE1, Bodnar et al., 1998; Jiang et al., 1999) provide a readily available source and represent the most tractable models. However, several of the immortalized cell lines have abnormal karyotypes, and often lack some physiological characteristics of RPE *in vivo*, so that their use comes with a potential trade-off. In many cases, though, a cultured cell line may possess the characteristics required for the particular study at hand. Importantly, these characteristics depend, not just on the origin of the cell line, but also on the conditions under which it has been cultured. Unfortunately, numerous published studies have used an RPE cell line where the cells do not have a basic epithelial organization, such as a cobblestone-like appearance and apical-basal polarity. That said, it is possible in some cases that the lack of RPE characteristics is less of a concern. For example, use of hTERT-RPE1 cells (see below) as a model for the study of the pocket cilium (Molla-Herman et al., 2010) does not require RPE-like functions. On the other hand, an RPE cell culture that is not well polarized is inappropriate for studying many key RPE functions. For example, manifestation of the apical-basal localization and motility of RPE organelles, such as phagosomes, lysosomes, and mitochondria, requires cells with apical-basal polarity that is determined by a well-differentiated cytoskeleton. The maturation and degradation of phagosomes from the tips of the photoreceptor outer segments involve an apical to basal migration of the phagosomes. Indeed, defects in phagosome migration inhibit degradation and lead to AMD-like pathology (Pfeffer and Philp, 2014; Jiang et al., 2015; Lakkaraju et al., 2020).

The RPE-J line was generated by simian virus 40 (SV40) transformation of primary rat RPE cells and was the first immortalized RPE cell line to be described (Nabi et al., 1993). In early

studies, RPE-J cultures were shown to possess numerous characteristics of differentiated RPE. They formed a cobblestone-like appearance based on circumferential localization of the tight-junction protein, ZO-1, exhibited extensive apical microvilli, and displayed significant trans-epithelial resistance (TER) ($350 \Omega \cdot \text{cm}^2$) (Nabi et al., 1993). However, the cells lacked some characteristic features dependent on polarity, such as the specific apical localization of the Na^+/K^+ -ATPase and neural cell adhesion molecule (NCAM) (Nabi et al., 1993), which are critical for RPE and photoreceptor function. Nearly three decades later, the RPE-J cell line continues to be used as an RPE model; however, the true passage number of these cells is often not known, and their ability to differentiate seems limited, at least by common culturing methods. Growing currently available RPE-J cell cultures in the presence of 10 nM retinoic acid has been reported to induce a differentiated RPE phenotype, however, resulting cultures typically lack a cobblestone-like appearance and demonstration of apical-basal differentiation (Kim et al., 2013). On the other hand, RPE-J cells use the same apical phagocytic receptors and signaling pathways as primary rat RPE to phagocytose shed outer segment fragments (Finnemann 2003). Overall, there has been minimal utility of RPE-J cells in modeling of AMD pathobiology *in vitro*; the focus of most of RPE-J studies has been on RPE cell biology.

The human telomerase (hTERT)-RPE1 cell line was derived from a young donor's RPE cells, using human telomerase reverse transcriptase activity. These cells have been reported to become pigmented in the absence of serum after four to eight weeks in culture and to express some RPE-associated proteins (e.g. cellular retinaldehyde-binding protein [CRALBP]) (Rambhatla et al., 2002). However, they do not form a differentiated epithelium with a cobblestone-like organization and have been used mainly for studies on the primary cilium (Molla-Herman et al., 2010). After a few days of serum starvation, ciliogenesis is robustly initiated, although the cilium typically extends between the cell and the substrate, rather than from an apical surface as in normal RPE cells. For vision scientists, the most applicable use of hTERT-RPE1 cells appears to be as a model for the photoreceptor cilium (Trivedi et al., 2012), since its cilium arises from a pocket (Molla-Herman et al., 2010; Chadha et al., 2021), like that of the photoreceptor cilium (Liu et al., 2007).

The first descriptions of the adult RPE-19 (ARPE-19) and D407 lines (Davis et al., 1995; Dunn et al., 1996) showed that they differentiate readily into polarized RPE cells. However, these cell lines have abnormal karyotypes (Davis et al., 1995; Fasler-Kan et al., 2018; Hazim et al., 2019), and having been passaged over many years have diminished ability to demonstrate characteristics of differentiated RPE (Strunnikova et al., 2010; Lehmann et al., 2014). Nevertheless, the ARPE-19 cell line remain widely used, and mimics many characteristics of RPE *in vivo* – *provided they are cultured under conditions that promote differentiation*.

Improved culture conditions that promote differentiation of ARPE-19 cells have been reported. They involve culture on a porous Transwell® filter and media additives that affect metabolism. One method involves the addition of pyruvate in high-glucose DMEM. Under these conditions, cells recapitulate key features of RPE cells, including RPE-specific differentiation markers, a cobblestone-like organization, polar expression of proteins, extensive microvilli, the ability to phagocytose, and secretion of VEGF (Ahmado et al.,

2011). The expression of the premelanosome marker Pmel17 was observed, although, as with the original study (Dunn et al., 1996), cylindrical melanosomes characteristic of the RPE were not evident. In addition, the cells did not exhibit a TER greater than $51 \Omega \cdot \text{cm}^2$. However, the same protocol employed by another group reported a TER of $126 \Omega \cdot \text{cm}^2$ (Samuel et al., 2017), but it required a three-to-four-month period for RPE differentiation. A more recent method incorporates the addition of nicotinamide instead of pyruvate, resulting in rapid differentiation of ARPE-19 cells. In the presence of nicotinamide, cells form a tightly-packed, cobblestone-like appearance after one week, and a well-polarized epithelium within four weeks (Hazim et al., 2019). While the epithelium still possesses a relatively low TER, this method of culturing ARPE-19 cells in media supplemented with nicotinamide preserves the ease of use inherent in a cell line.

ARPE-19 cells have already been used to study many characteristics of AMD, including EMT (Yang et al., 2021), inflammation (Tseng et al., 2013), phagocytosis defects (Xu et al., 2012, and complement activation (Chung et al., 2017; Fernandez-Godino et al., 2018). Unfortunately, most studies appear to have been performed on undifferentiated, or, at best, poorly differentiated cells. Nevertheless, the studies suggest that differentiated ARPE-19 cells may be amenable to such studies. Importantly, gene editing has been used successfully with ARPE-19 cells; for example, a mutant line was obtained by editing the *EFEMP1* gene to generate a mutation that underlies dominant macular degeneration (Fernandez-Godino et al., 2018). Thus, while there are limitations in the use of RPE cell lines, the use of appropriate culture conditions, in order to promote a differentiated epithelium, make the ARPE-19 cell line useful for various types of RPE studies, including those related to AMD (Table 1). A recent editorial by Pfeffer and Fliesler provides additional guidance for using ARPE19 cells with appropriate culture conditions (Pfeffer and Fliesler 2022).

PRIMARY RPE CELLS (MOUSE, PORCINE, BOVINE, MONKEY, HUMAN)

Primary RPE cultures have been established from freshly harvested retinas of mouse, porcine, or human donors. These cells are plated at confluence on collagen- or laminin or other extracellular matrices-coated semipermeable membrane inserts (Transwells®), culture conditions leading to cells that recapitulate several features of RPE *in situ*. The time to full maturation depends on the species: about two weeks for porcine RPE and more than six weeks for cultures established from human donors. After this period, the cultures have formed well-differentiated monolayers with tight junctions and TERs $>300 \Omega \cdot \text{cm}^2$. The cells exhibit a polarized RPE phenotype, with precisely organized microtubules that are essential for the appropriate localization of apical (e.g., Na^+ , K^+ -ATPase, $\alpha v \beta 5$ integrin, MCT1) and basolateral (e.g., MCT3, bestrophin-1, Stra6) proteins (Lakkaraju et al., 2020). The cells of these cultures degrade photoreceptor outer segments with kinetics comparable to RPE *in vivo*. Detailed protocols that have been validated in multiple publications are available (Blenkinsop et al., 2013; Gibbs and Williams, 2003; Maminishkis et al., 2006; Toops et al., 2014).

PRIMARY MOUSE RPE

Mouse RPE cultures are usually established from trypsinized RPE cells isolated from eyes of newborn pups and survive about 10 days in culture, which is sufficient for experiments using transfection, transduction, or live imaging approaches (Gibbs et al., 2003; Gibbs and Williams, 2003; Fernandez-Godino et al., 2016). These cultures can be generated from transgenic mice, which allows investigation of subcellular mechanisms that can contribute to RPE dysfunction and retinal degenerations (Nandrot et al., 2004; Esteve-Rudd et al., 2018; Jiang et al., 2015). Advantages of mouse RPE cultures include short post-mortem times and consistency of cultures due to inbred mouse lines. Some caveats are that cultures are easier to establish from younger mice than adult mice, which could limit the ability to model age-dependent disease pathology. On the other hand, younger mice have smaller eyes, so more eyes might be needed to generate a sufficient number of RPE cells. Another caveat, especially with regards to studying AMD, is that mice do not express key AMD-associated genes such as *ARMS2* and *CETP* and express only one isoform of APOE.

Recently, a new promising method of culturing an intact mouse RPE layer without the loss of its properties and function has been described (Shang et al. 2021). Briefly, the eye is dissected under sterile conditions to remove the anterior segment and the retina, followed by flattening the RPE-choroid-sclera explant on a polyvinylidene difluoride (PVDF) membrane with the sclera attached. Such RPE flat mounts can then be kept in culture for at least seven days without the loss of RPE viability and properties or significant alterations in the expression of RPE-specific genes. The main benefit of this method is that it is the gentlest technique to date for maintaining intact RPE cultures, where the procedure-induced stress to the RPE is minimal. An additional benefit is that the RPE can be obtained from any genetic background, including known mouse models for dry AMD (briefly discussed below), making it a good model for studying various aspects of AMD development and treatment *in vitro*.

One of the strongest genetic associations with the development of AMD has been shown to be a common polymorphism in the complement factor H (*CFH*) gene (Edwards et al. 2005; Hageman et al. 2005; Haines et al. 2005; Klein et al., 2005). Aged transgenic mice expressing the Y402H variant of the *CFH* gene on the *Cfh*^{-/-} background (*CFH-H/H*) developed an AMD-like phenotype only after being fed a high fat, cholesterol-enriched diet. Moreover, this phenotype was not associated with complement activation but rather with lipoprotein dysregulation, supporting a noncanonical role for CFH in AMD pathogenesis (Landowski et al. 2019). We speculate that cultured RPE flat mounts (Shang et al. 2021) from the aged Y402H transgenic mice may be an interesting and highly relevant *in vitro* model to study AMD pathogenesis. The applications may include gene therapy studies (silencing the existing H402 variant and replacing it with the low-risk Y402 variant of the gene) as well as investigations aimed at elucidating the interplay between the complement system and lipid homeostasis in AMD.

Another notable genetic risk factor for AMD is determined by the variants of the apolipoprotein E (*APOE*) gene (Klaver et al. 1998). While *APOE3* represents the wild-type variant, the presence of the *APOE2* allele increases the risk of developing AMD in humans

(reviewed in Hu et al. 2021). APOE2 is associated with a slightly increased risk of AMD (odds ratio [OR] 1.124–1.83) while APOE4 is associated with a slightly reduced risk (OR 0.43–0.81) (McKay et al. 2011; Hu et al. 2021). This is in stark contrast to the risk association of these alleles in Alzheimer's disease where APOE4 is a major genetic risk factor (OR 4.86), while APOE2 is protective (OR 0.60) (Ang et al. 2008). Potentially contributing to this paradox, the frequency distribution of the APOE4 allele halves between the ages of 60 and 85 years (McKay et al. 2011; Hu et al. 2021) which could diminish the effect of the APOE4 allele in late AMD in this age range. ApoE is known to be an abundant component of drusen in both healthy individuals and in AMD patients. Being secreted from both the apical and basal sides of the RPE, ApoE plays a role in lipid trafficking. Importantly, aged mice overexpressing human *APOE2*, *APOE3*, or *APOE4*, developed isoform-dependent pathologies when maintained on a high fat, cholesterol-rich (HFC) diet in which *APOE4* mice developed an AMD-like phenotype (Malek et al. 2005). In this original characterization of these *APOE* transgenic mice, all of the animals expressing the human ApoE were *APOE* homozygotes whereas, in the human association studies, the subjects were predominantly, if not exclusively, heterozygous for the *APOE2* or *APOE4* alleles (Malek et al. 2005). In addition, in the human studies, the effect of diet as a modifier of the *APOE* allele effect on AMD risk was not investigated. It should also be noted that the homozygote *APOE2* mice are 100% hyperlipoproteinemic unlike humans in which there is a 30% incidence (Sullivan et al. 1998), and this is not a feature of AMD. The AMD-like phenotype observed in old *APOE4* fed an HFC diet could be blocked with systemic anti-amyloid immunotherapy which resulted in structural preservation of the RPE, reduction of activated complement components in the sub-RPE deposits and protection of visual function (Ding et al. 2011). Another clear driver of AMD development is the dysregulation of lysosomal function in the RPE. To date, several animal models exist that develop an AMD-like phenotype due to defective lysosomes and deregulated autophagy, including the *Mcd/mcd* mice (enzymatically inactive cathepsin D) (Zhang et al. 2002), *Lamp 2* KO mice (Notomi et al., 2019), and *Cryba1* cKO mice (RPE-specific conditional knockout of gene encoding β A3/A1-crystallin) (Valapala et al. 2014; Zigler and Sinha 2015). Several genes involved in the lysosomes and autophagy have been shown to be critical in RPE cells (Frost et al., 2014; Gomez et al., 2018). It may be promising to use RPE cultures obtained from these animal models to further examine this relationship.

Despite several limitations, primary mouse RPE cultures – both from trypsinized cells and intact RPE monolayers, provide an excellent source to connect RPE biology to genetics, and to phenotypic data in animals, and its use continues to grow in the AMD field. Furthermore, mouse RPE cells can be expanded by one-two passages making them amenable to moderate drug screens. (Table 1).

PRIMARY PORCINE RPE

An increasing number of studies have used RPE from freshly harvested porcine eyes to establish well-polarized monolayers (Toops et al., 2014; Georgiannakis et al., 2015; Klingeborn et al., 2017). After approximately two weeks in anti-mycoplasma antibiotic (e.g. ciprofloxacin) on collagen-coated Transwell® filters, these monolayers express RPE polarity markers mentioned above, establish functional tight junctions, and have a TER >400

Ohms.cm² (Toops et al., 2014). An advantage of using porcine RPE cultures is the similarity between human and porcine immune systems (Henderson and Hicks 2002; Sanchez et al., 2011; Mair et al., 2014), which is important for investigating a disease with a strong immune component like AMD. In support of this, studies using porcine RPE have increased our insight into complement regulation in the RPE (Georgiannakis et al., 2015; Tan et al., 2016) and led to the discovery that intracellular complement activation is a novel modulator of RPE physiology (Kaur et al., 2018). Live imaging and bioinformatics analyses of the impact of *APOE* isoforms on porcine RPE cultures have identified that mitochondrial redox status regulates drusen nucleation in the RPE. Complement-mediated mitochondrial injury induces oxidation of proteins with reactive cysteines, such as APOE2 (the AMD risk isoform), which drives the formation of APOE biomolecular condensates as potential drusen precursors (La Cunza et al., 2021). Caveats for using porcine RPE cultures include the facts that: **i)** eyes are obtained from local abattoirs, meaning that tissue quality and therefore, ability to generate viable cultures, depends on the harvesting procedures used at different facilities; **ii)** pooling eyes from animals of different ages and sexes increases variability; and **iii)** RPE from some pig breeds are better able to generate healthy cultures compared to others, and provide sufficient quantity of cells for moderate size drug screens (Table 1).

PRIMARY BOVINE and MONKEY RPE

Previously primary cultures of bovine and monkey RPE cells have also been attempted (Oka et al., 1984; Pfeffer 1991; Hartnett et al., 2003; Becerra et al., 2004; Fronk and Vargis 2016). Bovine RPE cells required bovine serum for attachment, but serum free conditions led to better epithelial morphology in passaged cells (Oka et al. 1984). Hartnett et al determined that although the TER of primary bovine cultures increased for the first two weeks of cultures, it barely reached 100 Ohms.cm² and stayed stable only for additional two weeks. In co-culture with endothelial cells the TER of these cells dropped significantly (Hartnett et al., 2003). Pfeffer developed a protocol to derive confluent monolayers of monkey RPE cells and studied the effect of media components on cell proliferation and attachment to the substrate. These cells were found to secrete PEDF mainly apically, similar to cultures of fetal human RPE and iPSC-derived RPE (Becerra et al., 2004; Maminishkis et al., 2006; Sharma et al., 2019). Bovine globes are rather easier to obtain but monkey globes are relatively hard to obtain because of continually reduced usage of monkeys in research. Overall, neither of cultures were used extensively in AMD research and their current use in this field is negligible.

PRIMARY HUMAN RPE

Primary cultures from human donors have been generated from fetal RPE (Hu and Bok 2001; Maminishkis et al., 2006; Sonoda et al., 2009). These cultures are highly pigmented, exhibit a polarized epithelial morphology with tight junctions, and express RPE-specific proteins. Fully polarized monolayers develop after six to eight weeks in culture and display a very high TER (500–800 ohm.cm²). After one to three months of culture on semi-permeable membrane supports, human fetal RPE monolayers constitutively secrete deposits containing APOE into the basal matrix, which can be increased by exposing the cultures to active complement components (Johnson et al., 2011).

More recently a method for obtaining RPE cells from adult human RPE (ahRPE) monolayers has been described (Ferrington et al., 2017). Here, the cells are derived from cadaver donor eyes. RPE cultures established from adult donors have effectively been used to identify autophagic defects, mitochondrial dysfunction, secreted proteins, and decreased expression of nuclear hormone receptors in AMD donors compared with cultures established from donors without AMD (An et al., 2006; Hu et al., 2013; Ferrington et al., 2016; Ferrington et al., 2017; Choudhary et al., 2020; Zhang et al., 2020).

A significant obstacle to using human RPE cultures is the scarcity of donor tissue, ideally collected within short post-mortem times (Table 1). Moreover, RPE cells dedifferentiate with passaging and lose pigmentation, and acquire a fibroblastic morphology with loss of their cobblestone morphology. Some of these characteristics can be restored by long term culture (>8 weeks) on porous substrates, which facilitate the induction of polarity and related phenotypes (Hazim et al., 2019). That said, establishing primary RPE cultures would be especially useful when studying the epigenetic aspects of AMD induction. An increasing body of evidence suggests that epigenetics plays a role in AMD in the form of abnormal DNA and RNA methylations and histone modifications (reviewed in Li et al. 2020). We speculate that working with primary RPE cultures obtained directly from AMD donors, with their “naturally occurring” and unique patterns of epigenetic modifications, would allow researchers to identify important modifications and to potentially develop effective treatments to reverse them and to rescue RPE physiology and function. Despite the technical difficulties, donor-derived primary RPE seems to be ideal for this application, considering the complexity of the epigenetic modifications that may be hard, if not impossible, to recreate in other models (Table 1).

INDUCED PLURIPOTENT STEM CELL-DERIVED RPE

Over the last two decades, embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) have been developed as additional sources of differentiated human RPE cells (Sharma et al., 2020). Unlike the other sources of RPE cells discussed above, RPE differentiation from ESCs/iPSCs is a laborious and resource-consuming process. However, key advantages of this technology are: **(1)** the ability to obtain an unlimited supply of fully mature and functional RPE cells, making it feasible to perform disease modeling and high throughput drug screens that require large amounts of cells (Sharma et al., 2020; Miyagishima et al., 2021; Ferrer et al., 2014) and **(2)** derivation of patient-specific iPSC-derived RPE cells allowing the possibility of performing comparative analysis between diseased and healthy cells and correlating cellular endophenotypes with patient symptoms and genotypes (Sharma et al., 2020; Miyagishima et al., 2021).

iPSC-RPE cell cultures are both diverse and accessible, as iPSCs can be obtained by reprogramming of fibroblasts collected through skin biopsies or reprogramming of peripheral blood mononuclear cells through blood withdrawal. Their utility can be seen as three-fold: **(1)** iPSC-RPE may provide material for restoration/transplantation due to the very large numbers of high-quality cells available, a direction taken by several academic and commercial research groups globally. We will not elaborate on these efforts here; suffice it to say that numerous materials and methodologies are under investigation and being tested

in clinical trials (see review by Sharma et al 2020); (2) iPSC-RPE may provide high quality RPE cell culture models for mechanistic RPE research in general and specifically for AMD “disease-in-a-dish” research (May-Simera et al., 2018; Sharma et al., 2020) and; (3) as an extension from exploring AMD disease mechanisms and identification of differences at the cellular level, iPSC-RPE may be interrogated for responsiveness to interventions and therapies such that AMD patients or individuals with high risk of developing AMD may receive personalized therapy or preventive treatment (Sharma et al., 2019).

The initial observation of RPE differentiation from human ESCs dates to 2004, when ESCs were spontaneously differentiated into RPE cells (Klimanskaya et al., 2004). Over the last two decades multiple iterations of RPE differentiation protocols have been developed (see review by Sharma et al 2020). One key advancement in RPE differentiation methods is the use of what is called directed or guided differentiation methods (Idelson et al., 2009; Osakada et al., 2009; Sharma et al., 2019), using specific growth factors at defined timepoints to developmentally alter the fate of ESCs/iPSCs into RPE cells. Although the use of growth factors significantly increases the cost of RPE differentiation, there are multiple advantages to this approach: (1) it generates fully mature and functional RPE (May-Simera et al., 2018); (2) it improves the efficiency of differentiation from less than 10% in spontaneous differentiation to 60–80% with directed differentiation (Sharma et al., 2019); (3) it improves reproducibility of the protocol across multiple iPSC lines (Sharma et al., 2019); and, (4) it shortens the differentiation time from 30 weeks in spontaneous differentiation to 10 weeks in directed differentiation (Sharma et al., 2019).

iPSC-DERIVED RPE DIFFERENTIATION AND CHARACTERIZATION STANDARDS

One major concern with iPSC-RPE differentiation is that currently there are no standard protocols to differentiate and propagate iPSC-derived RPE. In addition to donor tissue source and individual donor characteristics, parameters that are likely to affect iPSC-RPE phenotype and function include substrate surface, plating density, feeding medium and frequency, and duration of culture. Depending upon the kind of substrate-coating, RPE cell change their gene expression profile especially of ECM-related genes (Sorkio et al., 2014). Unlike, immortalized cell lines, iPSC-derived RPE cells cannot be propagated forever. However, it may be possible to propagate iPSC-RPE cultures while maintaining their epithelial character, at least for a few passages, by using milder dissociation methods like low calcium containing medium, as suggested by Ramachandran Rao et al. 2018. There is nevertheless a need to develop standardized methods that are universally utilized for differentiation of iPSCs. In addition, there is a demand for commercial sources of AMD iPSC lines and derived RPE cells. The National Eye Institute recently started a repository of 65 AREDS2 iPSC lines at the New York Stem Cell Foundation (Wright et al., 2020). Some of the widely utilized iPSC-RPE commercial sources are iCell RPE from Fujifilm (catalog #R1102), Lagenlabs (RPE-catalog number not available), and Tempo Bioscience iRPE (Tempo-iRPE™).

However, there continues to be a need to functionally validate iPSC-RPE across labs so that results derived in different labs, using a given patient cell line, can be directly compared. A visual inspection of RPE monolayer confluency, hexagonality, and pigmentation along with expression analysis of a subset of genes is frequently used to validate RPE cells (Bharti et al., 2011). These assays do support a RPE phenotype but are not sensitive enough to compare and validate cells across multiple labs and from different AMD patients. Structural assessment of the RPE monolayer has been performed using scanning and transmission electron microscopy (Sharma et al., 2019). It has been shown that iPSC-derived RPE cells contain robust apically located pigment granules, basally located nuclei, tight junctions between neighboring cells, and confluent apical processes supporting fully polarized and mature feature of these cells (Miyagishima et al., 2016; Sharma et al., 2019). Functional assessment of the tight junctions is confirmed by measuring the TER of cells grown on semi-permeable Transwell® filters. As cells continue to mature, tight junctions seal the paracellular space increasing the ability of RPE cells to resist the flow of current passed via an electrode on the top and another on the bottom of RPE monolayer. TER measurement is one of the easiest assays to validate the quality of RPE cells derived from different patients or in different labs. TER values slowly increasing in the initial weeks of culture reaching a plateau of several hundred $\Omega \cdot \text{cm}^2$ have been demonstrated in iPSC-RPE cells derived from different donors (Miyagishima et al., 2016; Sharma et al., 2019). It is worth noting that TER measurements are extremely sensitive to outside variables like the composition, temperature, and pH of the cell culture medium and placement of electrodes (Srinivisan et al., 2015). Care must be taken to control these outside variables when comparing TER across labs or across cultures and additional assays of RPE barrier function must be performed. For instance, TER measurements in conjunction with quantification of apical and basal secretion of VEGF and PEDF are accepted assessments of barrier functions and RPE specific epithelial polarity. These tests have the benefit of being non-invasive and thus can be performed longitudinally to monitor cell differentiation over time of culture and under specific conditions of manipulation (e.g. stress challenge) or pharmacological treatment. Other common assessments include phagocytosis of photoreceptor outer segment fragments (POS), a key task of RPE cells in the eye. Phagocytosis by RPE cells in culture involves two well characterized surface receptors, $\alpha v \beta 5$ integrin and the TAM receptor MERTK, that function in POS recognition and internalization, respectively (Finnemann et al., 1997; D'Cruz et al., 2000). These receptors engage purified POS indirectly via extracellular bridge ligand proteins, e.g. MFG-E8 for $\alpha v \beta 5$ integrin (Nandrot et al., 2007), and Protein S for MERTK (Burstyn-Cohen et al., 2012). Phagocytosis assays where challenging RPE cells in culture with and without bridge ligand supplementation can therefore specify recognition and engulfment capacity of RPE cells (Mazzoni et al., 2019). These assessments require the addition of POS and ligand proteins at concentrations that match the levels of available cell surface phagocytic molecules, which may vary depending on cell origin or culture conditions. The kinetics of POS uptake vary significantly between iPSC-RPE cell populations. Both POS binding and engulfment are saturable processes. Thus, POS phagocytosis assays are informative and might be used to compare RPE functionality across cell sources and laboratories if they are optimized to yield maximal POS engulfment. Reporting of stringent assessment of phagocytic capacity of any RPE population should include quantification of two distinct characteristics, namely average numbers of particles

engulfed per cell and fraction of phagocytic cells in the population. With regard to AMD, the most critical stage of POS phagocytosis concerns the degradation of the engulfed POS membranes, with inefficient degradation likely contributing to lipid deposition. This degradation phase can be most readily studied by removing the POSs from the RPE cells after a short interval, and then following the subsequent degradation of the POS membranes that were engulfed during the “pulse” interval. The rate of POS degradation in iPSC-RPE cells have been found to compare well with *in vivo* rates, although variation among RPE cultures from different iPSC lines was observed further highlighting the need for standardized protocols for iPSC-RPE differentiation (Miyagishima et al., 2016; Sharma et al., 2019 Hazim et al., 2017).

Functional validation of iPSC-RPE not only helps with establishing high-quality cultures and improve rigor, but it also sets the stage of translational work when using such cells for disease modeling or drug discovery. For instance, assessment of RPE polarity, marker expression, and phagocytosis are sensitive and quantitative, thus allowing identification of modest differences between non-AMD/low-risk genotype and AMD/high-risk genotype RPE cells. Indeed, there is some evidence that reduced polarized growth factor secretion and phagocytic activity are associated with AMD/high-risk iPSC-RPE (Sharma et al., 2021). However, given the somewhat limited number of experimental parameters routinely tested for iPSC-RPE to date, additional insight into disease genotype or disease associated functional differences will likely be uncovered in future studies with more expansive testing. Interestingly donor dependent differences in purinergic receptor-based calcium signaling in iPSC-RPE cells has been reported, supporting the need for more nuanced assays to discern donor-specific differences in RPE cells (Miyagishima et al., 2016 & 2017). Observations from non iPSC adult human RPE studies suggest that quantifying F-actin stress fiber content of differentiated RPE may provide insight (Muller et al., 2018).

Unlike bona fide iPSC-RPE obtained through directing RPE differentiation from PSC, adult donor RPE-derived cultures may be maintained under conditions that promote proliferation and re-differentiation into large numbers of polarized, functional RPE cells, known as RPE stem cell-derived RPE (RPESC-RPE) (Salero et al., 2012; Blenkinsop et al., 2013). Compared to iPSC-RPE, RPESC-RPE generation and maintenance is economical and practical if donor globes, or posterior shells are available. Side-by-side comparison of RPESC-RPE from different donors has revealed that RPESC-RPE (derived from non-AMD donors only) falls into two distinct categories with respect to F-actin morphology and phagocytic function (Muller et al., 2018). Genotyping and AMD risk assessment of donors will be needed to determine if they underlie these or other line-to-line differences in RPESC-RPE functionality. Altogether, testing additional RPE properties should advance our insight into functional deficits of AMD RPE and may suggest new avenues for therapy or prevention. One exciting question that remains unanswered to date is whether we will be able to utilize functional assessment of specific parameters of iPSC-RPE cells in culture to predict AMD risk of donor individuals regardless of known low-risk/high-risk genotypes as this would be an enormous clinical advance.

Naturally, some of the early “disease in a dish” studies in the iPSC-RPE field focused on discovering the specific cellular phenotypes associated with the major risk-alleles for AMD

discovered in the *CFH* and *ARMS2/HTRA1* loci. Strikingly, these studies agree on the intriguing principal insight that AMD risk genotypes and/or AMD patient donor origin result in measurable functional differences among cell populations even if these are extensively propagated in cell culture. Moreover, the functional differences detected may be mitigated by manipulation of cell culture conditions. For instance, it was demonstrated that iPSC-RPE from AMD donors, some of whom carried the *ARMS2/HTRA1* high-risk alleles, normalized their gene and protein expression of pro-inflammatory markers including complement protein C3 following exposure to the metabolite precursor nicotinamide (Saini et al., 2017). A separate study comparing *ARMS2/HTRA1* high-risk versus low-risk iPSC-RPE shows association of decreased superoxide dismutase 2 and decreased antioxidant defense capacity with the high-risk genotype (Yang et al., 2014). Whether or not nicotinamide supplementation restores antioxidant capacity to high-risk AMD has not yet been reported. An important implication of these findings is that genotyping of known risk alleles of donor cells is essential to be able to distinguish variability among cell cultures due to technical issues and from differences in disease relevant genotypes.

Recently it was demonstrated that RPE derived from AMD iPSCs with the *CFH*(rs1061170, Y402H) high-risk allele show reduced mitochondrial function and increased expression of inflammatory markers as compared to cells with low-risk for the *CFH* allele (Ebeling et al., 2021). Importantly, AMD risk genotype or disease differences were readily detectable in iPSC-RPE only if these were subjected to moderate, sub-lethal levels of oxidative stress but not under normal cell culture conditions (Ebeling et al., 2021). Whether nicotinamide supplementation would ameliorate the mitochondrial deficiencies/stress responses was not tested. Others have pursued a similar strategy of comparing phenotypic differences between *CFH* low- and high-risk expressing RPE cells and also tested the effect of locally activated complement proteins C3a and C5a on iPSC-derived RPE cells (Sharma et al., 2021). Activation of local complement led to sub-RPE lipid deposits, loss of epithelial tight junctions, activation of the NF- κ B pathway, and downregulation of autophagy (Sharma et al., 2021). Cells with the high-risk allele showed predisposition to disease similar to previous observations (Sharma et al., 2021). A proof-of-concept drug screen identified two drugs, a dopamine receptor antagonist and a serine protease inhibitor, that could suppress the effect of activated complement on RPE cells (Sharma et al., 2021). While these studies will benefit from follow-up studies using iPSC-RPE generated through different protocols and with different types of starting donor tissue, they suggest that altered cell metabolism may contribute to or even underlie diverse AMD iPSC-RPE defects described earlier. Altogether, metabolic profiling of donor iPSC-RPE should be included in RPE validation assays to preclude studying secondary effects of metabolic deficiency (Table 1).

ORGAN-ON-A-CHIP

RPE cells have been utilized most intensively as a cellular model system for AMD, since many of the disease processes associated with AMD are related to RPE function. However, recent single cell sequencing studies of the retina, RPE and choroid demonstrate that AMD-associated genes are expressed in many different cell types beyond the RPE, including glial cells, vascular cells, fibroblasts, monocytes, photoreceptors, bipolar cells and horizontal cells (Menon et al., 2019; Cowan et al., 2020; Orozco et al., 2020). Furthermore, multiple RPE

subtypes that are differentially sensitive to AMD have been recently discovered (Ortolan et al., 2019). These finding suggests that modeling AMD in a 'generic' RPE cell and RPE alone may be too simplistic, and more complex model systems may be needed that include other retinal cell types. In early attempts to develop complex culture systems, RPE and endothelial cells were grown in two separate compartments of a transwell® culture system - RPE on top of the transwell insert membrane and endothelial cells at the bottom of the plastic dish well that holds the transwell insert. Despite cell culture medium separating the two cell types, this co-culture system showed improved TER of the RPE monolayer likely induced by cytokines secreted by endothelial cells in the cell culture medium (Benedicto et al, 2019). This work underscores that co-culture of different ocular cell types does affect their physiology. Bioengineering can aid in the development of *in vitro* models with higher complexity.

In recent years, organ-on-a-chip technology has demonstrated potential to establish *in vitro* models that can more closely mimic human tissue anatomy and functionality. Organ-on-chips are microfluidic cell culture systems that contain continuously perfused chambers with controlled, dynamic conditions for co-culturing multiple cell types, and simulating tissue- and organ-level physiology (Bhatia and Ingbar 2014). Organ-on-a-chip technology enables high-resolution, real-time imaging and *in vitro* analysis of biochemical, genetic and metabolic activities of living cells in the context of a functional tissue or organ.

Several organs-on-a-chip have been developed to model tissues relevant to AMD pathogenesis, in particular the RPE-choroid interface (Jong et al., 2021). The first organ-on-a-chip model of the RPE-choroid interactions consisted of ARPE-19 and HUVEC monolayers grown on opposite sides of a synthetic porous membrane, mimicking the *in vivo* anatomy where RPE cells are separated from the choroid by Bruch's membrane. The ARPE-19 and HUVEC monolayers were cultured under perfusion in separate microfluidic channels (Chen et al., 2017). The co-culture platform was used to study the effect of culture conditions on ARPE-19 cells and the subsequent response of HUVEC cells. ARPE-19 cells responded to lowered glucose and hypoxic microenvironments by increasing VEGF secretion, and HUVEC cells responded to increased concentrations of VEGF by moving through the pores towards the source of VEGF inside the microfluidic device. While this organ-on-a-chip model does not mimic the entire angiogenesis process, endothelial cell migration was used as a surrogate for the initial stage in angiogenic tube formation.

A second organ-on-a-chip device aimed to obtain a vascular network consisting of capillary-like structures. Endothelial cells (ECs) were allowed to self-assemble by embedding HUVECs in a fibrin scaffold together with lung fibroblasts to stabilize the vascular network (Chung et al., 2018). The microfluidic platform was designed to form a perfusable 3D blood vessel network adjacent to an ARPE-19 monolayer, close enough to interact. Instead of a membrane, fibrin channels were introduced among the ARPE-19 cells and the blood vessel network. The model was used to mimic the pathogenesis of CNV. In response to excessive VEGF concentrations, penetrating angiogenic sprouts from the blood vessel network resulted in breakdown of the RPE monolayer. The sprouting neovessels regressed when VEGF was added along with bevacizumab, an anti-VEGF agent used clinically for CNV treatment.

A similar vascular network-based organ-on-a-chip was developed using more physiologically relevant cells; human retinal microvascular ECs and primary human ocular choroidal fibroblasts were used to form a three-dimensional vascular network, and iPSC-derived RPE cells were co-cultured in direct contact with the vascular network (Paek et al., 2019). RPE maturation markers, such as melanosome number, were observed to increase in the co-culture.

Self-assembled vascular networks may lead to low reproducibility and consistency between different devices. To avoid this problem, an organ-on-a-chip device has been developed that consists of a monolayer of ARPE-19 cells in an open-top culture chamber, and a monolayer of HUVEC cells in a capillary-like channel, separated by a semipermeable membrane (Arik et al., 2021). The three-dimensional vascular structures within the chip were imaged by optical coherence tomography (OCT), a medical imaging technique that is routinely applied in ophthalmology. Upon inducing oxidative stress by treatment with hydrogen peroxide, a dose dependent increase in barrier permeability was observed using a dynamic assay for fluorescence tracing, analogous to the clinically used fluorescence angiography.

Another organ-on-a-chip concept, designed to reproduce the interface between the neural retina and the RPE has also recently been reported (Achberger et al., 2019). This device allows the co-culture of retinal organoids in advanced stages of maturation, containing photoreceptors, with apical exposure to an RPE monolayer. Phagocytosis of POS by the RPE was detected on-chip. Although the device is perfusable through a channel below the RPE compartment, there is no vascular system in this model.

For accurate disease modeling, it would be valuable to develop an organ-on-a-chip device that combines organoids, RPE and choroidal vasculature, thereby containing the wide variety of cell types that have been implicated in AMD pathology by single cell sequencing studies (Menon et al., 2019; Cowan et al., 2020; Orozco et al., 2020). In addition, it is necessary to extend the cellular lifespan of the cells on the chip, to allow increased maturation and observation of prolonged molecular processes (Jong et al., 2019). Further, it would be very useful to generate a multiplexed organ-on-a-chip device that allows high throughput screens for testing the effect of various disease stimuli and for drug screening purposes.

ASSAYS USING CULTURED RPE TO STUDY THE PATHOGENESIS OF AMD

As described in the previous sections, various cellular and molecular assays have been developed and used to not only validate the fidelity of *in vitro* cultures relative to the *in vivo* state, but also to characterize disease processes in the context of AMD pathology. Below we provide a brief review of culture models that present with AMD-associated morphological features and highlight a few assays relevant when studying AMD.

Drusen-like extracellular deposit formation

In vitro modeling of sub-RPE deposit formation has been achieved, to some degree, in a number of studies to date. A seminal study using ARPE-19 cells cultured over time observed an increase in the amount of condensed deposition of banded fibrillar material with a

periodicity similar to fibrous long spacing collagen, typical of basal laminar deposits seen in human AMD samples (Amin et al., 2004). Challenge with albumin and retinal homogenates led to a significant increase in the total amount of both membranous and fibrillar containing deposits. With the availability of human fetal RPE cells, the accumulation of basal laminar-like deposits containing fibrillar material, resembling fibrous long spacing collagen, has also been reported when cells were cultured for two to four months (Maminishkis et al., 2006). Exposure of early passage human fetal RPE cultures to human serum was shown to result in deposition of drusen-associated proteins including APOE, vitronectin, clusterin, serum amyloid P, as well as the terminal complement complex C5b-9 indicating activation of the complement system (Johnson et al., 2011). These studies collectively demonstrate that drusen originate from the RPE. A plausible mechanism for drusen biogenesis was recently identified using polarized porcine RPE cultures: complement-induced mitochondrial injury leads to aggregation of proteins with reactive cysteines such as APOE, thereby ‘nucleating’ drusen within the RPE (La Cunza et al., 2021).

Studies using stem cells as platforms for generating *in vitro* RPE model systems have shown that stressing a sub-population of self-renewing multipotent stem cells isolated from adult human RPE cells with the oxidant tert-butylhydroperoxide (TBHP) stimulates upregulation of drusen-associated crystallins, apolipoproteins, and extracellular matrix molecules intracellularly (Rabin et al., 2013). Notably, cultures of RPE cells derived from human iPSCs derived from AMD patients carrying the *ARMS/HTRA1* homozygous high-risk genotype secrete several AMD relevant proteins including complement proteins. Lipid droplet accumulation, visualized using Oil Red O histochemistry, has been reported in iPSC-derived RPE cells from patients homozygous for the low- and high-risk *CFH* genotypes (Hallam et al., 2017; Saini et al., 2017; Cerniauskas et al., 2020; Sharma et al., 2021). Finally, as touched on earlier, complement competent human serum treated iPSC-derived RPE cells from donors carrying the low- and high-risk *CFH* genotypes have been shown to induce extracellular APOE and lipid deposition (Sharma et al., 2021).

Extracellular deposits have also been reported in cultures of RPE cells isolated from non-human species, including mice and pigs. RPE harvested from mice with a dominant mutation in the EGF-containing fibulin-like ECM protein 1 (EFEMP1) produce basal deposits (Fernandez-Godina et al., 2015), whereas sub-RPE deposits containing drusen components have been observed in cultures harvested from porcine eyes, cultured for up to six months on polyester membrane inserts. The composition of the deposits was well-characterized and included neutral lipids as illustrated with Oil Red O staining, APOE, and mineralization as seen with Von Kossa staining and hydroxyapatite fluorescence labeling and mass spectrometry, adjacent to highly pigmented RPE cells, after as little as 12 weeks of culture (Pilgrim et al., 2017). Collectively, these model systems should be useful for studying the genesis of basal deposits and/or testing the ability of drugs to target and clear/block drusen-associated proteins.

It should be noted that *in vitro* models able to induce sub-retinal drusenoid deposits/reticular pseudodrusen, that accumulate on the apical side of RPE cells, are sparse (Rudolf et al., 2008; Zweifel et al., 2010). One study investigated the effect of low-lipid and oxidized lipid media on primary human fetal RPE cells treated with cholesterol carriers including

high density lipoprotein (HDL) and apolipoprotein A-1 (APOA-1). They found that upon exposure of fetal RPE cells to oxidized LDL, apical cholesterol efflux increased significantly as compared to low-lipid media conditions whereas the basolateral cholesterol efflux was barely changed. These changes in vectorial lipid transport in stressed RPE cells suggests potential mechanisms underlying the formation of drusen versus sub-retinal drusenoid deposits (Lyssenko et al., 2018). Consistently Miller et al 2021 showed polarized APOE secretion in primary human RPE cells. Under oxidative stress conditions basolateral APOE secretion dropped favoring apically directed drusenoid formation (Miller et al., 2021). These culture conditions could potentially be used to evaluate the efficacy of drugs targeting apical versus basal RPE deposits.

Complement pathway-based assays

Genome-wide association studies have identified genetic variants in or near the *CFH*, *CFB*, *C3*, complement *C9*, *CFI* and vitronectin (*VTN*) genes, underscoring an important role for genetic variation in the complement system in the pathogenesis AMD (Fritsche et al., 2016; Jong et al., 2019). Various studies have evaluated the role of the complement system in RPE cells using various assays. Cultured RPE cells constitutively express various components of the complement system, including *C3*, *C5*, *CFB*, *CFH*, *CFI*, *CD46*, *CD59*, *CLU* and *VTN* (Anderson et al., 2010; Sugita et al., 2018). The effect of disease triggers or genotypes on the complement system in RPE cells can either be measured by quantifying the expression of complement gene expression or proteins, or by measuring deposition of complement activation fragments such as C3a, C3d, C5a or the membrane attack complex (MAC) using immunofluorescence (Jong et al., 2021).

The expression of complement factors is increased by exposure of RPE cells to inflammatory conditions such as interferon- γ treatment or in the presence of supernatant from T helper type 1 cells as well as by exposure to A2E and hypoxia (Fanelli et al., 2017; Parmer et al., 2018). Increased MAC deposition was observed in response to hypoxic conditions (Fanelli et al., 2017), exposure to serum (Galloway et al., 2017), and cells carrying the *CFHY402H* genotype had significantly increased C3d deposition compared to *CFH402Y* cells (Keir et al., 2017). RPE cells are, like host-cells in general, protected from MAC induced lysis via several mechanisms, and therefore MAC deposition on RPE cells is generally sub-lytic (Morgan 2016).

Knock down of *CFH* in hTERT RPE-1 cells results in increased *C3* expression and elevated C3 and/or C3b concentrations in the supernatant (Armento et al., 2020). In iPSC-RPE carrying high-risk genotypes at the *CFH* (Y402H) and *ARMS2/HTRA1* loci, expression of the *CFI*, *CFH* and *FHL-1* mRNA levels are significantly elevated while *C3* mRNA is reduced (Hallam et al., 2017). CFH and CFI secretion from iPSC-RPE were shown to be functional, as incubation with RPE supernatant results in degradation of purified C3b to iC3b. Deposit formation is observed in RPE cultures carrying high-risk genotypes, which was demonstrated by immunostaining for the terminal complement complex C5b-9 and for APOE (Sharma et al., 2021).

Several studies have examined the effect of exposing RPE cells to complement proteins. Treatment of primary RPE cells with the anaphylatoxin C3a increases VEGF expression

(Nozaki et al., 2006), and stimulation of fetal RPE with C3a leads to increased basal accumulation of collagens IV and VI, decreased proteasome activity and increased MMP-2 activity (Fernandez-Godino and Pierce, 2018). C3a and C5a treatment triggers an intracellular Ca²⁺ response (Busch et al., 2017). Exposure of fetal RPE cultures to human serum as a source of complement resulted in a selective, deposit-associated accumulation of additional known drusen components, including vitronectin, clusterin, and serum amyloid P (Johnson et al., 2011). Exposure of iPSC-derived RPE cells to complement competent human serum as a source of anaphylatoxins C3a and C5a leads to a dramatic increase in APOE-positive sub-RPE deposits, irrespective of *CFHY402* genotype (Sharma et al., 2021). APOE and lipid deposition are stimulated by C3a-C3aR1 and C5a-C5aR1 -induced NF-κB activation, autophagy downregulation, and dysregulated calcium homeostasis. The RPE can also generate biologically active C3a fragments and the consequent C3a-C3aR signaling leads to aberrant activation of mTOR, which inhibits autophagy and reprograms RPE metabolism (Toops et al. 2015; Kaur et al 2018). Sub-lytic MAC deposition on RPE cells can cause mitochondrial fragmentation (Tan et al., 2016) and increase secretion of IL-6, IL-8, and MCP-1 (Lueck et al., 2011), emphasizing a pro-inflammatory response of the RPE to complement stressors.

Cholesterol efflux assays

Given the notable accumulation of esterified cholesterol in Bruch's membrane with age and the abundance of lipids and cholesterol carriers in drusen and sub-RPE deposits observed in AMD donor tissue (Curcio, 2018), cholesterol assays are used in studying AMD pathobiology and assessing potential treatments. The most established assays involve measuring ³H-cholesterol efflux via cholesterol acceptors including APOA1, APOE, and HDL (Biswas et al., 2017), fluorescent based assays of cholesterol efflux rate (Tsai et al., 2021), uptake of oxidized LDL by RPE cells (Gnanaguru et al., 2016), histochemical and immunohistochemical staining of RPE cultures evaluating intracellular and extracellular lipid distribution using filipin, Oil Red O, bodipy, and adipored (Choudhary et al., 2020; Pilgrim et al., 2017; Sharma et al., 2021; Toops et al. 2015; Tan et al., 2016), as well as protein and gene expression (Liu et al., 2014; PMID: 24393350).

AMD-associated genetic variants in lipid metabolism have been identified in or near the ATP-binding cassette transporter 1 (*ABCA1*), *APOE*, cholesteryl transfer protein (*CETP*) and hepatic lipase C (*LIPC*) genes (Fritsche et al., 2016; van Leeuwen et al., 2018). *ABCA1* is strongly expressed in the RPE and is required for lipid metabolism and export (Storti et al., 2019). The expression of *ABCA1* was found to be decreased in iPSC-RPE carrying the increased risk *ABCA1* genotype treated with a Liver X receptor (LXR) agonist, a regulator of cholesterol homeostasis, compared to iPSC-RPE cells carrying the reduced risk *ABCA1* genotype (Storti et al., 2019). A cholesterol efflux assay demonstrated that reduced *ABCA1* expression hampered cholesterol efflux and led to lipid accumulation in iPSC-RPE cells (Peters et al., 2021). Increasing *ABCA1* expression by a small molecule LXR agonist prevented cholesterol accumulation in primary porcine RPE cultures (Toops et al. 2015; Tan et al., 2016).

Redox status-based assays

Oxidative stress is common to all three non-genetic risk factors of AMD – aging, smoking, and high-fat diet (Datta et al., 2017). AMD disease processes are thought to be triggered when the redox status of RPE cells switches from an anti-oxidant stage to a pro-oxidant stage. Damaged mitochondria are a source of reactive oxygen species (ROS), if not removed by mitophagy and has been shown to be associated with AMD (Karunadharam et al., 2010). Mitophagy can be analyzed by measuring the expression of mitochondrial proteins, quantifying the levels of mitochondrial DNA, measuring the activity of enzyme Citrate Synthetase, and by electron microscopy (Williams et al., 2017). Downregulation of mitophagy and mitochondrial activity has been noted in AMD patient derived iPSC-RPE cells (Golestaneh et al., 2016). Another mechanism regulating cellular redox homeostasis is regulated by transcription factor NRF2 that is upstream of genes involved in managing cellular oxidative stress response (see Datta et al 2017 for more details). It directly regulates the expression of several key oxidative stress pathway genes, such as Catalase and SOD. In addition, NRF2 has been shown to regulate levels of cellular anti-oxidants glutathione and thioredoxin. NRF2 expression is shown to decrease with aging (Suzuki et al., 2008) and after acute oxidative stress in RPE cells (Sachdeva et al., 2014). Measurement of the expression of NRF2 target genes, and the levels of glutathione and thioredoxin provides a critical readout of cellular redox status and is directly associated with AMD pathogenesis.

CONCLUSIONS AND RECOMMENDATIONS

Due to space limitations, we were only able to report a fraction of the literature, featuring some of the known inducers of AMD in the context of developing *in vitro* models for AMD research. A very detailed review on the risk factors for progression and development of AMD was published recently (Heesterbeek et al. 2020) and can be used as a source for developing *in vitro* models using AMD inducers that have not been featured in this report.

The improvement in the morphology and function of non-human and human derived RPE cell lines have paved the way for their use in pre-clinical studies testing potential therapeutics and pharmaceuticals. These cell-based models have primarily included single cell platforms, but also more complex cocultures (RPE and choroidal ECs), as well as organoids. The advantages of culture systems are their potential reliability, consistency, and low cost compared to *in vivo* studies. Additionally, single cell model systems allow for testing the effect of drugs in a cell-focused manner (Ferrer et al., 2014; Sharma et al., 2021) whereas the more complex coculture and organoid systems are a step closer to the physiological microenvironment, in which there are heterotypic intercellular communications. The need for high throughput platforms to test potential therapies has driven the creation and characterization of *in vitro* model systems that recapitulate morphologic and functional abnormalities associated with human AMD.

Going forward, we provide recommendations for these *in vitro* models described here. The immortalized cell lines each were generated from a single individual, therefore they do not recapitulate natural variation that occurs in the general population. Moreover, their use in an undifferentiated state has frequently led to results that may not reflect RPE biology. However, knockouts or knock-ins of genes of interest can easily be generated in these cell

lines using genome editing/CRISPR technology. Furthermore, their ease of access makes them an attractive tool for several labs, and recent work focusing on metabolic conditions have now demonstrated simple methods for establishing better polarized ARPE-19 cell cultures. Primary RPE cells and iPSC-RPE cells have been validated in several labs for physiologically relevant RPE phenotype and can recapitulate natural variation of patients or genetics of mouse models. One major drawback of these models is that they require specialized training and handling to achieve consistent and high-quality cultures reducing their accessibility. Furthermore, not all AMD-associated genetic variants have been routinely genotyped (Jong et al., 2021). In order to compare results using different studies, and to interpret the effects of genetic variants in these cultures it might be ideal to genotype all possible AMD-associated genetic variants and rare variants (e.g. the *CFH* and *CFI* genes) (Fritsche et al., 2016). However, this may be time-consuming and expensive. Therefore, since the complement factor H – complement Factor H Related 5 (*CFH-CFHR5*) locus on chromosome 1q32 and the *ARMS2/HtrA* serine peptidase 1 (*HTRA1*) locus on 10q26 account for the majority of genetic susceptibility for AMD (Pappas et al., 2021), we recommend that at a minimum, these two loci be genotyped. To improve usability of the currently available *in vitro* models for different aspects of AMD research, it is critical to develop standardized protocols and quality control criteria such that results can be compared across labs.

ACKNOWLEDGMENTS:

Authors would like to thank the Ryan Initiative for Macular Research for bringing together researchers for a focused discussion on *in vitro* models of macular degeneration. This review is an outcome of that discussion.

FUNDING:

National Eye Institute (NEI) Intramural funds (KB); NEI EY032751 (GM), EY028160 (GM), Research to Prevent Blindness (Duke Eye Center); NEI EY031748 (CBR), P30 EY005722 (to Duke Eye Center); EY026539 (PAD); EY031594–01A1 (DS); NEI EY030668 (AL), Research to Prevent Blindness/American Macular Degeneration Foundation Catalyst Award (AL), BrightFocus Foundation M2021020I (AL); NEI EY027442 (DSW), EY031109 (DSW), and P30 EY000331 (to UCLA - DSW), and Foundation Fighting Blindness (DSW).

REFERENCES

- Achberger K, Probst C, Haderspeck J, Bolz S, Rogal J, Chuchuy J, Nikolova M, Cora V, Antkowiak L, Haq W, Shen N, Schenke-Layland K, Ueffing M, Liebau S, Loskill P. Merging organoid and organ-on-a-chip technology to generate complex multi-layer tissue models in a human retina-on-a-chip platform. *Elife* 2019 Aug 27; 8: e46188 [PubMed: 31451149]
- Ahmado A, Carr AJ, Vugler AA, Semo M, Gias C, Lawrence JM, Chen LL, Chen FK, Turowski P, da Cruz L, Coffey PJ. Induction of differentiation by pyruvate and DMEM in the human retinal pigment epithelium cell line ARPE-19. *Invest Ophthalmol Vis Sci* 2011 Sep 9;52(10):7148–59. [PubMed: 21743014]
- Amin S, Chong NH, Bailey TA, Zhang J, Knupp C, Cheetham ME, Greenwood J, Luthert PJ. Modulation of Sub-RPE deposits *in vitro*: a potential model for age-related macular degeneration. *Invest Ophthalmol Vis Sci* 2004 May;45(5):1281–8. [PubMed: 15111578]
- An E, Lu X, Flippin J, Devaney JM, Halligan B, Hoffman EP, Strunnikova N, Csaky K, Hathout Y. Secreted proteome profiling in human RPE cell cultures derived from donors with age related macular degeneration and age matched healthy donors. *J Proteome Res* 2006 Oct;5(10):2599–610. [PubMed: 17022631]
- Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT, Curletti CR, Hancox LS, Hu J, Ebright JN, Malek G, Hauser MA, Rickman CB, Bok D, Hageman GS, Johnson LV. The pivotal role of

- the complement system in aging and age-related macular degeneration: hypothesis re-visited. *Prog Retin Eye Res* 2010 Mar;29(2):95–112. [PubMed: 19961953]
- Ang LS, Cruz RP, Hendel A, Granville DJ. Apolipoprotein E, an important player in longevity and age-related diseases. *Exp Gerontol* 2008 Jul;43(7):615–622. [PubMed: 18468826]
- Arık YB, Buijsman W, Loessberg-Zahl J, Cuartas-Vélez C, Veenstra C, Logtenberg S, Grobbink AM, Bergveld P, Gagliardi G, den Hollander AI, Bosschaart N, van den Berg A, Passier R, van der Meer AD. Microfluidic organ-on-a-chip model of the outer blood-retinal barrier with clinically relevant read-outs for tissue permeability and vascular structure. *Lab Chip* 2021 Jan 21;21(2):272–283. [PubMed: 33346294]
- Armento A, Honisch S, Panagiotakopoulou V, Sonntag I, Jacob A, Bolz S, Kilger E, Deleidi M, Clark S, Ueffing M. Loss of Complement Factor H impairs antioxidant capacity and energy metabolism of human RPE cells. *Sci Rep* 2020 Jun 25;10(1):10320. [PubMed: 32587311]
- Becerra SP, Fariss RN, Wu YQ, Montuenga LM, Wong P, Pfeffer BA. Pigment epithelium-derived factor in the monkey retinal pigment epithelium and interphotoreceptor matrix: apical secretion and distribution. *Exp Eye Res* 2004 Feb;78(2):223–34. [PubMed: 14729355]
- Benedicto I, Lehmann GL, Ginsberg M, Nolan DJ, Bareja R, Elemento O, Salfati Z, Alam NM, Prusky GT, Llanos P, Rabbany SY, Maminishkis A, Miller SS, Rafii S, Rodriguez-Boulan E. Concerted regulation of retinal pigment epithelium basement membrane and barrier function by angiocrine factors. *Nat Commun* 2017 May 19;8:15374. [PubMed: 28524846]
- Bhatia SN, Ingber DE. Microfluidic organs-on-chips. *Nat Biotechnol* 2014 Aug;32(8):760–72 [PubMed: 25093883]
- Bharti K, Nguyen MT, Skuntz S, Bertuzzi S, Arnheiter H. The other pigment cell: specification and development of the pigmented epithelium of the vertebrate eye. *Pigment Cell Res* 2006 Oct;19(5):380–94. [PubMed: 16965267]
- Bharti K, Miller SS, Arnheiter H. The new paradigm: retinal pigment epithelium cells generated from embryonic or induced pluripotent stem cells. *Pigment Cell Melanoma Res* 2011 Feb;24(1):21–34. [PubMed: 20846177]
- Biswas L, Zhou X, Dhillon B, Graham A, Shu X. Retinal pigment epithelium cholesterol efflux mediated by the 18 kDa translocator protein, TSPO, a potential target for treating age-related macular degeneration. *Hum Mol Genet* 2017 Nov 15;26(22):4327–4339. [PubMed: 28973423]
- Blenkinsop TA, Salero E, Stern JH, Temple S. The culture and maintenance of functional retinal pigment epithelial monolayers from adult human eye. *Methods Mol Biol* 2013; 945:45–65. [PubMed: 23097100]
- Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE. Extension of life-span by introduction of telomerase into normal human cells. *Science* 1998 Jan 16;279(5349):349–52. [PubMed: 9454332]
- Burstyn-Cohen T, Lew ED, Través PG, Burrola PG, Hash JC, Lemke G. Genetic dissection of TAM receptor-ligand interaction in retinal pigment epithelial cell phagocytosis. *Neuron* 2012 Dec 20;76(6):1123–32. [PubMed: 23259948]
- Busch C, Annamalai B, Abdusalamova K, Reichhart N, Huber C, Lin Y, Jo EAH, Zipfel PF, Skerka C, Wildner G, Diedrichs-Möhrling M, Rohrer B, Strauß O. Anaphylatoxins Activate Ca²⁺, Akt/PI3-Kinase, and FOXO1/FoxP3 in the Retinal Pigment Epithelium. *Front Immunol* 2017 Jun 15;8:703. [PubMed: 28663750]
- Cerniauskas E, Kurzawa-Akanbi M, Xie L, Hallam D, Moya-Molina M, White K, Steel D, Doherty M, Whitfield P, Al-Aama J, Armstrong L, Kavanagh D, Lambris JD, Korolchuk VI, Harris C, Lako M. Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of age-related macular degeneration by restoring lysosomal function. *Stem Cells Transl Med* 2020 Dec;9(12):1585–1603. [PubMed: 32815311]
- Chadha A, Paniagua AE, Williams DS. Comparison of Ciliary Targeting of Two Rhodopsin-Like GPCRs: Role of C-Terminal Localization Sequences in Relation to Cilium Type. *J Neurosci* 2021 Sep 8;41(36):7514–7531. [PubMed: 34301828]
- Chen LJ, Ito S, Kai H, Nagamine K, Nagai N, Nishizawa M, Abe T, Kaji H. Microfluidic co-cultures of retinal pigment epithelial cells and vascular endothelial cells to investigate choroidal angiogenesis. *Sci Rep* 2017 Jun 14;7(1):3538. [PubMed: 28615726]

- Choudhary M, Ismail EN, Yao PL, Tayyari F, Radu RA, Nusinowitz S, Boulton ME, Apte RS, Ruberti JW, Handa JT, Tontonoz P, Malek G. LXR_s regulate features of age-related macular degeneration and may be a potential therapeutic target. *JCI Insight* 2020 Jan 16;5(1):e131928.
- Chung EJ, Efstathiou NE, Konstantinou EK, Maidana DE, Miller JW, Young LH, Vavvas DG. AICAR suppresses TNF- α -induced complement factor B in RPE cells. *Sci Rep* 2017 Dec 15;7(1):17651. [PubMed: 29247196]
- Chung M, Lee S, Lee BJ, Son K, Jeon NL, Kim JH. Wet-AMD on a Chip: Modeling Outer Blood-Retinal Barrier In Vitro. *Adv Healthc Mater* 2018 Jan;7(2).
- Cowan CS, Renner M, De Gennaro M, Gross-Scherf B, Goldblum D, Hou Y, Munz M, Rodrigues TM, Krol J, Szikra T, Cuttat R, Waldt A, Papasaikas P, Diggelmann R, Patino-Alvarez CP, Galliker P, Spirig SE, Pavlinic D, Gerber-Hollbach N, Schuierer S, Srdanovic A, Balogh M, Panero R, Kusnyerik A, Szabo A, Stadler MB, Orgül S, Picelli S, Hasler PW, Hierlemann A, Scholl HPN, Roma G, Nigsch F, Roska B. **Cell Types of the Human Retina and Its Organoids at Single-Cell Resolution.** *Cell* 2020 Sep 17;182(6):1623–1640.e34. [PubMed: 32946783]
- Curcio CA. Soft Drusen in Age-Related Macular Degeneration: Biology and Targeting Via the Oil Spill Strategies. *Invest Ophthalmol Vis Sci* 2018 Mar 20;59(4):
- D’Cruz PM, Yasumura D, Weir J, Matthes MT, Abderrahim H, LaVail MM, Vollrath D. Mutation of the receptor tyrosine kinase gene *Mertk* in the retinal dystrophic RCS rat. *Hum Mol Genet* 2000 Mar 1;9(4):645–51. [PubMed: 10699188]
- Davis AA, Bernstein PS, Bok D, Turner J, Nachtigal M, Hunt RC. A human retinal pigment epithelial cell line that retains epithelial characteristics after prolonged culture. *Invest Ophthalmol Vis Sci* 1995 Apr;36(5):955–64. [PubMed: 7706045]
- Datta S, Cano M, Ebrahimi K, Wang L, Handa JT. The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD. *Prog Retin Eye Res* 2017 Sep; 60:201–218. [PubMed: 28336424]
- Ding JD, Johnson LV, Herrmann R, Farsiu S, Smith SG, Groelle M, Mace BE, Sullivan P, Jamison JA, Kelly U, Harrabi O, Bollini SS, Dilley J, Kobayashi D, Kuang B, Li W, Pons J, Lin JC, Bowes Rickman C. Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. *Proc Natl Acad Sci U S A* 2011 Jul 12;108(28):E279–87. [PubMed: 21690377]
- Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. *Exp Eye Res* 1996 Feb;62(2):155–69. [PubMed: 8698076]
- Ebeling MC, Geng Z, Kapphahn RJ, Roehrich H, Montezuma SR, Dutton JR, Ferrington DA. Impaired Mitochondrial Function in iPSC-Retinal Pigment Epithelium with the Complement Factor H Polymorphism for Age-Related Macular Degeneration. *Cells* 2021 Apr 2;10(4):789. [PubMed: 33918210]
- Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. *Science* 2005 Apr 15;308(5720):421–4. [PubMed: 15761121]
- Esteve-Rudd J, Hazim RA, Diemer T, Paniagua AE, Volland S, Umapathy A, Williams DS. Defective phagosome motility and degradation in cell nonautonomous RPE pathogenesis of a dominant macular degeneration. *Proc Natl Acad Sci U S A* 2018 May 22;115(21):5468–5473. [PubMed: 29735674]
- Fanelli G, Gonzalez-Cordero A, Gardner PJ, Peng Q, Fernando M, Kloc M, Farrar CA, Naeem A, Garred P, Ali RR, Sacks SH. Human stem cell-derived retinal epithelial cells activate complement via collectin 11 in response to stress. *Sci Rep* 2017 Nov 7;7(1):14625. [PubMed: 29116192]
- Fasler-Kan E, Aliu N, Wunderlich K, Ketterer S, Ruggiero S, Berger S, Meyer P. The Retinal Pigment Epithelial Cell Line (ARPE-19) Displays Mosaic Structural Chromosomal Aberrations. *Methods Mol Biol* 2018;1745:305–314. [PubMed: 29476476]
- Fernandez-Godino R, Garland DL, Pierce EA. A local complement response by RPE causes early-stage macular degeneration. *Hum Mol Genet* 2015 Oct 1;24(19):5555–69. [PubMed: 26199322]
- Fernandez-Godino R, Garland DL, Pierce EA. Isolation, culture and characterization of primary mouse RPE cells. *Nat Protoc* 2016 Jul;11(7):1206–18. [PubMed: 27281648]

- Fernandez-Godino R, Pierce EA. C3a triggers formation of sub-retinal pigment epithelium deposits via the ubiquitin proteasome pathway. *Sci Rep* 2018 Jun 26;8(1):9679. [PubMed: 29946065]
- Fernandez-Godino R, Bujakowska KM, Pierce EA. Changes in extracellular matrix cause RPE cells to make basal deposits and activate the alternative complement pathway. *Hum Mol Genet* 2018 Jan 1;27(1):147–159. [PubMed: 29095988]
- Ferrer M, Corneo B, Davis J, Wan Q, Miyagishima KJ, King R, Maminishkis A, Marugan J, Sharma R, Shure M, Temple S, Miller S, Bharti K. A multiplex high-throughput gene expression assay to simultaneously detect disease and functional markers in induced pluripotent stem cell-derived retinal pigment epithelium. *Stem Cells Transl Med* 2014 Aug;3(8):911–22. [PubMed: 24873859]
- Ferrington DA, Kapphahn RJ, Leary MM, Atilano SR, Terluk MR, Karunadharna P, Chen GK, Ratnapriya R, Swaroop A, Montezuma SR, Kenney MC. Increased retinal mtDNA damage in the CFH variant associated with age-related macular degeneration. *Exp Eye Res* 2016 Apr;145:269–277. [PubMed: 26854823]
- Ferrington DA, Ebeling MC, Kapphahn RJ, Terluk MR, Fisher CR, Polanco JR, Roehrich H, Leary MM, Geng Z, Dutton JR, Montezuma SR. Altered bioenergetics and enhanced resistance to oxidative stress in human retinal pigment epithelial cells from donors with age-related macular degeneration. *Redox Biol* 2017 Oct;13:255–265. [PubMed: 28600982]
- Finnemann SC, Bonilha VL, Marmorstein AD, Rodriguez-Boulan E. Phagocytosis of rod outer segments by retinal pigment epithelial cells requires alpha(v)beta5 integrin for binding but not for internalization. *Proc Natl Acad Sci U S A* 1997 Nov 25;94(24):12932–7. [PubMed: 9371778]
- Finnemann SC. Focal adhesion kinase signaling promotes phagocytosis of integrin-bound photoreceptors. *EMBO J* 2003 Aug 15;22(16):4143–54. [PubMed: 12912913]
- Fritsche LG, Igl W, Bailey JN, Grassmann F, Sengupta S, Bragg-Gresham JL, Burdon KP, Hebbaring SJ, Wen C, Gorski M, Kim IK, Cho D, Zack D, Souied E, Scholl HP, Bala E, Lee KE, Hunter DJ, Sardell RJ, Mitchell P, Merriam JE, Cipriani V, Hoffman JD, Schick T, Lechanteur YT, Guymer RH, Johnson MP, Jiang Y, Stanton CM, Buitendijk GH, Zhan X, Kwong AM, Boleda A, Brooks M, Gieser L, Ratnapriya R, Branham KE, Foerster JR, Heckenlively JR, Othman MI, Vote BJ, Liang HH, Souzeau E, McAllister IL, Isaacs T, Hall J, Lake S, Mackey DA, Constable IJ, Craig JE, Kitchner TE, Yang Z, Su Z, Luo H, Chen D, Ouyang H, Flagg K, Lin D, Mao G, Ferreyra H, Stark K, von Strachwitz CN, Wolf A, Brandl C, Rudolph G, Olden M, Morrison MA, Morgan DJ, Schu M, Ahn J, Silvestri G, Tironi EE, Park KH, Farrer LA, Orlin A, Brucker A, Li M, Curcio CA, Mohand-Saïd S, Sahel JA, Audo I, Benchaboune M, Cree AJ, Rennie CA, Goverdhan SV, Grunin M, Hagbi-Levi S, Campochiaro P, Katsanis N, Holz FG, Blond F, Blanché H, Deleuze JF, Igo RP Jr, Truitt B, Peachey NS, Meuer SM, Myers CE, Moore EL, Klein R, Hauser MA, Postel EA, Courtenay MD, Schwartz SG, Kovach JL, Scott WK, Liew G, Tan AG, Gopinath B, Merriam JC, Smith RT, Khan JC, Shahid H, Moore AT, McGrath JA, Laux R, Brantley MA Jr, Agarwal A, Ersoy L, Caramoy A, Langmann T, Saksens NT, de Jong EK, Hoyng CB, Cain MS, Richardson AJ, Martin TM, Blangero J, Weeks DE, Dhillon B, van Duijn CM, Doheny KF, Romm J, Klaver CC, Hayward C, Gorin MB, Klein ML, Baird PN, den Hollander AI, Fauser S, Yates JR, Allikmets R, Wang JJ, Schaumberg DA, Klein BE, Hagstrom SA, Chowers I, Lotery AJ, Léveillard T, Zhang K, Brilliant MH, Hewitt AW, Swaroop A, Chew EY, Pericak-Vance MA, DeAngelis M, Stambolian D, Haines JL, Iyengar SK, Weber BH, Abecasis GR, Heid IM. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. *Nat Genet* 2016 Feb;48(2):134–43. [PubMed: 26691988]
- Fronk AH, Vargis E. Methods for culturing retinal pigment epithelial cells: a review of current protocols and future recommendations. *J Tissue Eng* 2016 Jul 12;7:2041731416650838.
- Frost LS, Mitchell CH, Boesze-Battaglia K. Autophagy in the eye: implications for ocular cell health. *Exp Eye Res* 2014 Jul;124:56–66. [PubMed: 24810222]
- Galloway CA, Dalvi S, Hung SSC, MacDonald LA, Latchney LR, Wong RCB, Guymer RH, Mackey DA, Williams DS, Chung MM, Gamm DM, Pébay A, Hewitt AW, Singh R. Drusen in patient-derived hiPSC-RPE models of macular dystrophies. *Proc Natl Acad Sci U S A* 2017 Sep 26;114(39):E8214–E8223. [PubMed: 28878022]
- Georgiannakis A, Burgoyne T, Lueck K, Futter C, Greenwood J, Moss SE. Retinal Pigment Epithelial Cells Mitigate the Effects of Complement Attack by Endocytosis of C5b-9. *J Immunol* 2015 Oct 1;195(7):3382–9. [PubMed: 26324770]

- Gibbs D, Williams DS. Isolation and culture of primary mouse retinal pigmented epithelial cells. *Adv Exp Med Biol* 2003;533:347–52. [PubMed: 15180284]
- Gibbs D, Kitamoto J, Williams DS. Abnormal phagocytosis by retinal pigmented epithelium that lacks myosin VIIa, the Usher syndrome 1B protein. *Proc Natl Acad Sci U S A* 2003 May 27;100(11):6481–6. [PubMed: 12743369]
- Golestaneh N, Chu Y, Cheng SK, Cao H, Poliakov E, Berinstein DM. Repressed SIRT1/PGC-1 α pathway and mitochondrial disintegration in iPSC-derived RPE disease model of age-related macular degeneration. *J Transl Med* 2016 Dec 20;14(1):344. [PubMed: 27998274]
- Gómez NM, Lu W, Lim JC, Kiselyov K, Campagno KE, Grishchuk Y, Slaughter SA, Pfeffer BA, Fliesler SJ, Mitchell CH. Robust lysosomal calcium signaling through channel TRPML1 is impaired by lysosomal lipid accumulation. *FASEB J* 2018 Feb;32(2):782–794. [PubMed: 29030399]
- Gnanaguru G, Choi AR, Amarnani D, D'Amore PA. Oxidized Lipoprotein Uptake Through the CD36 Receptor Activates the NLRP3 Inflammasome in Human Retinal Pigment Epithelial Cells. *Invest Ophthalmol Vis Sci* 2016 Sep 1;57(11):4704–12. [PubMed: 27607416]
- Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, Hageman JL, Stockman HA, Borchardt JD, Gehrs KM, Smith RJ, Silvestri G, Russell SR, Klaver CC, Barbazetto I, Chang S, Yannuzzi LA, Barile GR, Merriam JC, Smith RT, Olsh AK, Bergeron J, Zernant J, Merriam JE, Gold B, Dean M, Allikmets R. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. *Proc Natl Acad Sci U S A* 2005 May 17;102(20):7227–32. [PubMed: 15870199]
- Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, Spencer KL, Kwan SY, Noureddine M, Gilbert JR, Schetz-Boutaud N, Agarwal A, Postel EA, Pericak-Vance MA. Complement factor H variant increases the risk of age-related macular degeneration. *Science* 2005 Apr 15;308(5720):419–21. [PubMed: 15761120]
- Hallam D, Collin J, Bojic S, Chichagova V, Buskin A, Xu Y, Lafage L, Otten EG, Anyfantis G, Mellough C, Przyborski S, Alharthi S, Korolchuk V, Lotery A, Saretzki G, McKibbin M, Armstrong L, Steel D, Kavanagh D, Lako M. An Induced Pluripotent Stem Cell Patient Specific Model of Complement Factor H (Y402H) Polymorphism Displays Characteristic Features of Age-Related Macular Degeneration and Indicates a Beneficial Role for UV Light Exposure. *Stem Cells* 2017 Nov;35(11):2305–2320. [PubMed: 28913923]
- Hartnett ME, Lappas A, Darland D, McColm JR, Lovejoy S, D'Amore PA. Retinal pigment epithelium and endothelial cell interaction causes retinal pigment epithelial barrier dysfunction via a soluble VEGF-dependent mechanism. *Exp Eye Res* 2003 Nov;77(5):593–9. [PubMed: 14550401]
- Hazim RA, Karumbayaram S, Jiang M, Dimashkie A, Lopes VS, Li D, Burgess BL, Vijayaraj P, Alva-Ornelas JA, Zack JA, Kohn DB, Gomperts BN, Pyle AD, Lowry WE, Williams DS. Differentiation of RPE cells from integration-free iPSCs and their cell biological characterization. *Stem Cell Res Ther* 2017 Oct 2;8(1):217. [PubMed: 28969679]
- Hazim RA, Volland S, Yen A, Burgess BL, Williams DS. Rapid differentiation of the human RPE cell line, ARPE-19, induced by nicotinamide. *Exp Eye Res* 2019 Feb;179:18–24. [PubMed: 30336127]
- Heesterbeek TJ, Lorés-Motta L, Hoyng CB, Lechanteur YTE, den Hollander AI. Risk factors for progression of age-related macular degeneration. *Ophthalmic Physiol Opt* 2020 Mar;40(2):140–170. [PubMed: 32100327]
- Hendrickson A, Hicks D. Distribution and density of medium- and short-wavelength selective cones in the domestic pig retina. *Exp Eye Res* 2002 Apr;74(4):435–44. [PubMed: 12076087]
- Hu J, Bok D. A cell culture medium that supports the differentiation of human retinal pigment epithelium into functionally polarized monolayers. *Mol Vis* 2001 Feb 7;7:14–9. [PubMed: 11182021]
- Hu P, Herrmann R, Bednar A, Saloupis P, Dwyer MA, Yang P, Qi X, Thomas RS, Jaffe GJ, Boulton ME, McDonnell DP, Malek G. Aryl hydrocarbon receptor deficiency causes dysregulated cellular matrix metabolism and age-related macular degeneration-like pathology. *Proc Natl Acad Sci U S A* 2013 Oct 22;110(43):E4069–78. [PubMed: 24106308]
- Hu ML, Quinn J, Xue K. Interactions between Apolipoprotein E Metabolism and Retinal Inflammation in Age-Related Macular Degeneration. *Life (Basel)* 2021 Jun 29;11(7):635. [PubMed: 34210002]

- Idelson M, Alper R, Obolensky A, Ben-Shushan E, Hemo I, Yachimovich-Cohen N, Khaner H, Smith Y, Wisner O, Gropp M, Cohen MA, Even-Ram S, Berman-Zaken Y, Matzrafi L, Rechavi G, Banin E, Reubinoff B. Directed differentiation of human embryonic stem cells into functional retinal pigment epithelium cells. *Cell Stem Cell* 2009 Oct 2;5(4):396–408. [PubMed: 19796620]
- Jiang XR, Jimenez G, Chang E, Frolkis M, Kusler B, Sage M, Beeche M, Bodnar AG, Wahl GM, Tlsty TD, Chiu CP. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. *Nat Genet* 1999 Jan;21(1):111–4. doi: 10.1038/5056. [PubMed: 9916802]
- Jiang M, Esteve-Rudd J, Lopes VS, Diemer T, Lillo C, Rump A, Williams DS. Microtubule motors transport phagosomes in the RPE, and lack of KLC1 leads to AMD-like pathogenesis. *J Cell Biol* 2015 Aug 17;210(4):595–611. [PubMed: 26261180]
- Johnson LV, Forest DL, Banna CD, Radeke CM, Maloney MA, Hu J, Spencer CN, Walker AM, Tsie MS, Bok D, Radeke MJ, Anderson DH. Cell culture model that mimics drusen formation and triggers complement activation associated with age-related macular degeneration. *Proc Natl Acad Sci U S A* 2011 Nov 8;108(45):18277–82. [PubMed: 21969589]
- de Jong S, Gagliardi G, Garanto A, de Breuk A, Lechanteur YTE, Katti S, van den Heuvel LP, Volokhina EB, den Hollander AI. Implications of genetic variation in the complement system in age-related macular degeneration. *Prog Retin Eye Res* 2021 Sep;84:100952. [PubMed: 33610747]
- Karunadharma PP, Nordgaard CL, Olsen TW, Ferrington DA. Mitochondrial DNA damage as a potential mechanism for age-related macular degeneration. *Invest Ophthalmol Vis Sci* 2010 Nov;51(11):5470–9. [PubMed: 20505194]
- Kaur G, Tan LX, Rathnasamy G, La Cunza N, Germer CJ, Toops KA, Fernandes M, Blenkinsop TA, Lakkaraju A. Aberrant early endosome biogenesis mediates complement activation in the retinal pigment epithelium in models of macular degeneration. *Proc Natl Acad Sci U S A* 2018 Sep 4;115(36):9014–9019. [PubMed: 30126999]
- Keir LS, Firth R, Aponik L, Feitelberg D, Sakimoto S, Aguilar E, Welsh GI, Richards A, Usui Y, Satchell SC, Kuzmuk V, Coward RJ, Goult J, Bull KR, Sharma R, Bharti K, Westenskow PD, Michael IP, Saleem MA, Friedlander M. VEGF regulates local inhibitory complement proteins in the eye and kidney. *J Clin Invest* 2017 Jan 3;127(1):199–214. [PubMed: 27918307]
- Kim JY, Zhao H, Martinez J, Doggett TA, Kolesnikov AV, Tang PH, Ablonczy Z, Chan CC, Zhou Z, Green DR, Ferguson TA. Noncanonical autophagy promotes the visual cycle. *Cell* 2013 Jul 18;154(2):365–76. [PubMed: 23870125]
- Klaver CC, Kliffen M, van Duijn CM, Hofman A, Cruts M, Grobbee DE, van Broeckhoven C, de Jong PT. Genetic association of apolipoprotein E with age-related macular degeneration. *Am J Hum Genet* 1998 Jul;63(1):200–6. [PubMed: 9634502]
- Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, SanGiovanni JP, Mane SM, Mayne ST, Bracken MB, Ferris FL, Ott J, Barnstable C, Hoh J. Complement factor H polymorphism in age-related macular degeneration. *Science* 2005 Apr 15;308(5720):385–9. [PubMed: 15761122]
- Klimanskaya I, Hipp J, Rezaei KA, West M, Atala A, Lanza R. Derivation and comparative assessment of retinal pigment epithelium from human embryonic stem cells using transcriptomics. *Cloning Stem Cells* 2004;6(3):217–45. [PubMed: 15671670]
- Klingeborn M, Dismuke WM, Skiba NP, Kelly U, Stamer WD, Bowes Rickman C. Directional Exosome Proteomes Reflect Polarity-Specific Functions in Retinal Pigmented Epithelium Monolayers. *Sci Rep* 2017 Jul 7;7(1):4901. [PubMed: 28687758]
- La Cunza N, Tan LX, Thamban T, Germer CJ, Rathnasamy G, Toops KA, Lakkaraju A. Mitochondria-dependent phase separation of disease-relevant proteins drives pathological features of age-related macular degeneration. *JCI Insight* 2021 May 10;6(9):e142254.
- Landowski M, Kelly U, Klingeborn M, Groelle M, Ding JD, Grigsby D, Bowes Rickman C. Human complement factor H Y402H polymorphism causes an age-related macular degeneration phenotype and lipoprotein dysregulation in mice. *Proc Natl Acad Sci U S A* 2019 Feb 26;116(9):3703–3711. [PubMed: 30808757]
- Lakkaraju A, Umapathy A, Tan LX, Daniele L, Philp NJ, Boesze-Battaglia K, Williams DS. The cell biology of the retinal pigment epithelium. *Prog Retin Eye Res* 2020 Feb 24:100846.

- Lehmann GL, Benedicto I, Philp NJ, Rodriguez-Boulan E. Plasma membrane protein polarity and trafficking in RPE cells: past, present and future. *Exp Eye Res* 2014 Sep;126:5–15. [PubMed: 25152359]
- Li X, He S, Zhao M. An Updated Review of the Epigenetic Mechanism Underlying the Pathogenesis of Age-related Macular Degeneration. *Aging Dis* 2020 Oct 1;11(5):1219–1234. [PubMed: 33014534]
- Li S, Li X, He S, Zheng Q, Chen X, Wu X, Xu W. Early Postoperative Rotational stability and its related factors of a single-piece acrylic toric intraocular lens. *Eye (Lond)* 2020 Mar;34(3):474–479. [PubMed: 31300809]
- Liu Q, Tan G, Levenkova N, Li T, Pugh EN Jr, Rux JJ, Speicher DW, Pierce EA. The proteome of the mouse photoreceptor sensory cilium complex. *Mol Cell Proteomics* 2007 Aug;6(8):1299–317 [PubMed: 17494944]
- Liu K, Chen LJ, Lai TY, Tam PO, Ho M, Chiang SW, Liu DT, Young AL, Yang Z, Pang CP. Genes in the high-density lipoprotein metabolic pathway in age-related macular degeneration and polypoidal choroidal vasculopathy. *Ophthalmology* 2014 Apr;121(4):911–6. [PubMed: 24393350]
- Lueck K, Wasmuth S, Williams J, Hughes TR, Morgan BP, Lommatzsch A, Greenwood J, Moss SE, Pauleikhoff D. Sub-lytic C5b-9 induces functional changes in retinal pigment epithelial cells consistent with age-related macular degeneration. *Eye (Lond)* 2011 Aug;25(8):1074–82. [PubMed: 21597483]
- Lysenko NN, Haider N, Picataggi A, Cipollari E, Jiao W, Phillips MC, Rader DJ, Chavali VRM. Directional ABCA1-mediated cholesterol efflux and apoB-lipoprotein secretion in the retinal pigment epithelium. *J Lipid Res* 2018 Oct;59(10):1927–1939. [PubMed: 30076206]
- Mair KH, Sedlak C, Käser T, Pasternak A, Levast B, Gerner W, Saalmüller A, Summerfield A, Gerdtz V, Wilson HL, Meurens F. The porcine innate immune system: an update. *Dev Comp Immunol* 2014 Aug;45(2):321–43. [PubMed: 24709051]
- Malek G, Johnson LV, Mace BE, Saloupis P, Schmechel DE, Rickman DW, Toth CA, Sullivan PM, Bowes Rickman C. Apolipoprotein E allele-dependent pathogenesis: a model for age-related retinal degeneration. *Proc Natl Acad Sci U S A* 2005 Aug 16;102(33):11900–5. [PubMed: 16079201]
- Maminishkis A, Chen S, Jalickee S, Banzon T, Shi G, Wang FE, Ehalt T, Hammer JA, Miller SS. Confluent monolayers of cultured human fetal retinal pigment epithelium exhibit morphology and physiology of native tissue. *Invest Ophthalmol Vis Sci* 2006 Aug;47(8):3612–24. [PubMed: 16877436]
- May-Simera HL, Wan Q, Jha BS, Hartford J, Khristov V, Dejene R, Chang J, Patnaik S, Lu Q, Banerjee P, Silver J, Insinna-Kettenhofen C, Patel D, Lotfi M, Malicdan M, Hotaling N, Maminishkis A, Sridharan R, Brooks B, Miyagishima K, Gunay-Aygun M, Pal R, Westlake C, Miller S, Sharma R, Bharti K. Primary Cilium-Mediated Retinal Pigment Epithelium Maturation Is Disrupted in Ciliopathy Patient Cells. *Cell Rep* 2018 Jan 2;22(1):189–205. [PubMed: 29298421]
- Mazzoni F, Mao Y, Finnemann SC. Advanced Analysis of Photoreceptor Outer Segment Phagocytosis by RPE Cells in Culture. *Methods Mol Biol* 2019;1834:95–108. [PubMed: 30324439]
- McKay GJ, Patterson CC, Chakravarthy U, Dasari S, Klaver CC, Vingerling JR, Ho L, de Jong PT, Fletcher AE, Young IS, Seland JH, Rahu M, Soubrane G, Tomazzoli L, Topouzis F, Vioque J, Hingorani AD, Sofat R, Dean M, Sawitzke J, Seddon JM, Peter I, Webster AR, Moore AT, Yates JR, Cipriani V, Fritsche LG, Weber BH, Keilhauer CN, Lotery AJ, Ennis S, Klein ML, Francis PJ, Stambolian D, Orlin A, Gorin MB, Weeks DE, Kuo CL, Swaroop A, Othman M, Kanda A, Chen W, Abecasis GR, Wright AF, Hayward C, Baird PN, Guymer RH, Attia J, Thakkinstian A, Silvestri G. Evidence of association of APOE with age-related macular degeneration: a pooled analysis of 15 studies. *Hum Mutat* 2011 Dec;32(12):1407–16. [PubMed: 21882290]
- McKay GJ, Silvestri G, Chakravarthy U, Dasari S, Fritsche LG, Weber BH, Keilhauer CN, Klein ML, Francis PJ, Klaver CC, Vingerling JR, Ho L, De Jong PT, Dean M, Sawitzke J, Baird PN, Guymer RH, Stambolian D, Orlin A, Seddon JM, Peter I, Wright AF, Hayward C, Lotery AJ, Ennis S, Gorin MB, Weeks DE, Kuo CL, Hingorani AD, Sofat R, Cipriani V, Swaroop A, Othman M, Kanda A, Chen W, Abecasis GR, Yates JR, Webster AR, Moore AT, Seland JH, Rahu M, Soubrane G, Tomazzoli L, Topouzis F, Vioque J, Young IS, Fletcher AE, Patterson CC. Variations

- in apolipoprotein E frequency with age in a pooled analysis of a large group of older people. *Am J Epidemiol* 2011 Jun 15;173(12):1357–64. [PubMed: 21498624]
- Menon M, Mohammadi S, Davila-Velderrain J, Goods BA, Cadwell TD, Xing Y, Stemmer-Rachamimov A, Shalek AK, Love JC, Kellis M, Hafler BP. Single-cell transcriptomic atlas of the human retina identifies cell types associated with age-related macular degeneration. *Nat Commun* 2019 Oct 25;10(1):4902. [PubMed: 31653841]
- Miller JML, Zhang Q, Johnson MW. Regression of drusen or vitelliform material heralding geographic atrophy: correlation between clinical observations and basic science. *Graefes Arch Clin Exp Ophthalmol* 2021 Jul;259(7):2051–2053. [PubMed: 33547965]
- Miyagishima KJ, Wan Q, Corneo B, Sharma R, Lotfi MR, Boles NC, Hua F, Maminishkis A, Zhang C, Blenkinsop T, Khristov V, Jha BS, Memon OS, D'Souza S, Temple S, Miller SS, Bharti K. In Pursuit of Authenticity: Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Clinical Applications. *Stem Cells Transl Med* 2016 Nov;5(11):1562–1574. [PubMed: 27400791]
- Miyagishima KJ, Wan Q, Miller SS, Bharti K. A basis for comparison: sensitive authentication of stem cell derived RPE using physiological responses of intact RPE monolayers. *Stem Cell Transl Investig* 2017;4:e1497.
- Miyagishima KJ, Sharma R, Nimmagadda M, Clore-Gronenborn K, Qureshy Z, Ortolan D, Bose D, Farnoodian M, Zhang C, Fausey A, Sergeev YV, Abu-Asab M, Jun B, Do KV, Kautzman Guerin MA, Calandria J, George A, Guan B, Wan Q, Sharp RC, Cukras C, Sieving PA, Hufnagel RB, Bazan NG, Boesze-Battaglia K, Miller S, Bharti K. AMPK modulation ameliorates dominant disease phenotypes of CTRP5 variant in retinal degeneration. *Commun Biol* 2021 Dec 9;4(1):1360. [PubMed: 34887495]
- Molla-Herman A, Ghossoub R, Blisnick T, Meunier A, Serres C, Silbermann F, Emmerson C, Romeo K, Bourdoncle P, Schmitt A, Saunier S, Spassky N, Bastin P, Benmerah A. The ciliary pocket: an endocytic membrane domain at the base of primary and motile cilia. *J Cell Sci* 2010 May 15;123(Pt 10):1785–95. [PubMed: 20427320]
- Morgan BP. The membrane attack complex as an inflammatory trigger. *Immunobiology* 2016 Jun;221(6):747–51. [PubMed: 25956457]
- Müller C, Charniga C, Temple S, Finnemann SC. Quantified F-Actin Morphology Is Predictive of Phagocytic Capacity of Stem Cell-Derived Retinal Pigment Epithelium. *Stem Cell Reports* 2018 Mar 13;10(3):1075–1087. [PubMed: 29456184]
- Nabi IR, Mathews AP, Cohen-Gould L, Gundersen D, Rodriguez-Boulan E. Immortalization of polarized rat retinal pigment epithelium. *J Cell Sci* 1993 Jan;104 (Pt 1):37–49. [PubMed: 8383696]
- Nandrot EF, Kim Y, Brodie SE, Huang X, Sheppard D, Finnemann SC. Loss of synchronized retinal phagocytosis and age-related blindness in mice lacking alphavbeta5 integrin. *J Exp Med* 2004 Dec 20;200(12):1539–45. [PubMed: 15596525]
- Nandrot EF, Anand M, Almeida D, Atabai K, Sheppard D, Finnemann SC. Essential role for MFG-E8 as ligand for alphavbeta5 integrin in diurnal retinal phagocytosis. *Proc Natl Acad Sci U S A* 2007 Jul 17;104(29):12005–10. [PubMed: 17620600]
- Notomi S, Ishihara K, Efstathiou NE, Lee JJ, Hisatomi T, Tachibana T, Konstantinou EK, Ueta T, Murakami Y, Maidana DE, Ikeda Y, Kume S, Terasaki H, Sonoda S, Blanz J, Young L, Sakamoto T, Sonoda KH, Saftig P, Ishibashi T, Miller JW, Kroemer G, Vavvas DG. Genetic LAMP2 deficiency accelerates the age-associated formation of basal laminar deposits in the retina. *Proc Natl Acad Sci U S A* 2019 Nov 19;116(47):23724–23734. [PubMed: 31699817]
- Nozaki M, Raisler BJ, Sakurai E, Sarma JV, Barnum SR, Lambris JD, Chen Y, Zhang K, Ambati BK, Baffi JZ, Ambati J. Drusen complement components C3a and C5a promote choroidal neovascularization. *Proc Natl Acad Sci U S A* 2006 Feb 14;103(7):2328–33. [PubMed: 16452172]
- Oka MS, Landers RA, Bridges CD. A serum-free defined medium for retinal pigment epithelial cells. *Exp Cell Res* 1984 Oct;154(2):537–47. [PubMed: 6383855]
- Orozco LD, Chen HH, Cox C, Katschke KJ Jr, Arceo R, Espiritu C, Caplazi P, Nghiem SS, Chen YJ, Modrusan Z, Dressen A, Goldstein LD, Clarke C, Bhangale T, Yaspan B, Jeanne M, Townsend MJ, van Lookeren Campagne M, Hackney JA. Integration of eQTL and a Single-Cell Atlas in the

- Human Eye Identifies Causal Genes for Age-Related Macular Degeneration. *Cell Rep* 2020 Jan 28;30(4):1246–1259.e6. [PubMed: 31995762]
- Ortolan D, Sharma R, Volkov A, Maminishkis A, Hotaling NA, Huryan LA, Cukras C, Di Marco S, Bisti S, Bharti K. Single-cell-resolution map of human retinal pigment epithelium helps discover subpopulations with differential disease sensitivity. *Proc Natl Acad Sci U S A* 2022 May 10;119(19):e2117553119. [PubMed: 35522714]
- Osakada F, Ikeda H, Sasai Y, Takahashi M. Stepwise differentiation of pluripotent stem cells into retinal cells. *Nat Protoc* 2009;4(6):811–24. [PubMed: 19444239]
- Paek J, Park SE, Lu Q, Park KT, Cho M, Oh JM, Kwon KW, Yi YS, Song JW, Edelstein HI, Ishibashi J, Yang W, Myerson JW, Kiseleva RY, Aprelev P, Hood ED, Stambolian D, Seale P, Muzykantov VR, Huh D. Microphysiological Engineering of Self-Assembled and Perfusible Microvascular Beds for the Production of Vascularized Three-Dimensional Human Microtissues. *ACS Nano* 2019 Jul 23;13(7):7627–7643. [PubMed: 31194909]
- Pappas CM, Zouache MA, Matthews S, Faust CD, Hageman JL, Williams BL, Richards BT, Hageman GS. Protective chromosome 1q32 haplotypes mitigate risk for age-related macular degeneration associated with the CFH-CFHR5 and ARMS2/HTRA1 loci. *Hum Genomics* 2021 Sep 25;15(1):60. [PubMed: 34563268]
- Parmar VM, Parmar T, Arai E, Perusek L, Maeda A. A2E-associated cell death and inflammation in retinal pigmented epithelial cells from human induced pluripotent stem cells. *Stem Cell Res* 2018 Mar;27:95–104. [PubMed: 29358124]
- Pfeffer BA Improved methodology for cell culture of human and monkey retinal pigment epithelium. *Prog. In Retinal Research* 1991 10:251–291.
- Pfeffer BA, Fliesler SJ. Reassessing the suitability of ARPE-19 cells as a valid model of native RPE biology. *Exp Eye Res* 2022 Jun;219:109046. [PubMed: 35314139]
- Peters F, Atac DF, Berger W, Den Hollander AI, Grimm C Downregulation of *ABCA1* in iPSC-derived RPE cells impaired cholesterol efflux leading to intracellular lipid accumulation. *Investigative Ophthalmology & Visual Science* June 2021, Vol.62, 248.
- Pfeffer BA, Philp NJ. Cell culture of retinal pigment epithelium: Special Issue. *Exp Eye Res* 2014 Sep;126:1–4. [PubMed: 25152358]
- Pilgrim MG, Lengyel I, Lanzirotti A, Newville M, Fearn S, Emri E, Knowles JC, Messinger JD, Read RW, Guidry C, Curcio CA. Subretinal Pigment Epithelial Deposition of Drusen Components Including Hydroxyapatite in a Primary Cell Culture Model. *Invest Ophthalmol Vis Sci* 2017 Feb 1;58(2):708–719. [PubMed: 28146236]
- Rabin DM, Rabin RL, Blenkinsop TA, Temple S, Stern JH. Chronic oxidative stress upregulates Drusen-related protein expression in adult human RPE stem cell-derived RPE cells: a novel culture model for dry AMD. *Aging (Albany NY)* 2013 Jan;5(1):51–66. [PubMed: 23257616]
- Rakoczy PE, Zhang D, Robertson T, Barnett NL, Papadimitriou J, Constable IJ, Lai CM. Progressive age-related changes similar to age-related macular degeneration in a transgenic mouse model. *Am J Pathol* 2002 Oct;161(4):1515–24. [PubMed: 12368224]
- Ramachandra Rao S, Pfeffer BA, Más Gómez N, Skelton LA, Keiko U, Sparrow JR, Rowsam AM, Mitchell CH, Fliesler SJ. Compromised phagosome maturation underlies RPE pathology in cell culture and whole animal models of Smith-Lemli-Opitz Syndrome. *Autophagy* 2018;14(10):1796–1817. [PubMed: 29979914]
- Rambhatla L, Chiu CP, Glickman RD, Rowe-Rendleman C. In vitro differentiation capacity of telomerase immortalized human RPE cells. *Invest Ophthalmol Vis Sci* 2002 May;43(5):1622–30. [PubMed: 11980883]
- Rein DB, Wittenborn JS, Zhang X, Honeycutt AA, Lesesne SB, Saaddine J. Vision Health Cost-Effectiveness Study Group. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. *Arch Ophthalmol* 2009 Apr;127(4):533–40. [PubMed: 19365036]
- Rudolf M, Malek G, Messinger JD, Clark ME, Wang L, Curcio CA. Sub-retinal drusenoid deposits in human retina: organization and composition. *Exp Eye Res* 2008 Nov;87(5):402–8. [PubMed: 18721807]

- Sachdeva MM, Cano M, Handa JT. Nrf2 signaling is impaired in the aging RPE given an oxidative insult. *Exp Eye Res* 2014 Feb;119:111–4. [PubMed: 24216314]
- Saini JS, Corneo B, Miller JD, Kiehl TR, Wang Q, Boles NC, Blenkinsop TA, Stern JH, Temple S. Nicotinamide Ameliorates Disease Phenotypes in a Human iPSC Model of Age-Related Macular Degeneration. *Cell Stem Cell* 2017 May 4;20(5):635–647.e7. [PubMed: 28132833]
- Salero E, Blenkinsop TA, Corneo B, Harris A, Rabin D, Stern JH, Temple S. Adult human RPE can be activated into a multipotent stem cell that produces mesenchymal derivatives. *Cell Stem Cell* 2012 Jan 6;10(1):88–95. [PubMed: 22226358]
- Samuel W, Jaworski C, Postnikova OA, Kutty RK, Duncan T, Tan LX, Poliakov E, Lakkaraju A, Redmond TM. Appropriately differentiated ARPE-19 cells regain phenotype and gene expression profiles similar to those of native RPE cells. *Mol Vis* 2017 Mar 5;23:60–89. [PubMed: 28356702]
- Sanchez I, Martin R, Ussa F, Fernandez-Bueno I. The parameters of the porcine eyeball. *Graefes Arch Clin Exp Ophthalmol* 2011 Apr;249(4):475–82. [PubMed: 21287191]
- Shang P, Stepicheva N, Teel K, McCauley A, Fitting CS, Hose S, Grebe R, Yazdankhah M, Ghosh S, Liu H, Strizhakova A, Weiss J, Bhutto IA, Luty GA, Jayagopal A, Qian J, Sahel JA, Samuel Zigler J Jr, Handa JT, Sergeev Y, Rajala RVS, Watkins S, Sinha D. β A3/A1-crystallin regulates apical polarity and EGFR endocytosis in retinal pigmented epithelial cells. *Commun Biol* 2021 Jul 8;4(1):850. [PubMed: 34239035]
- Sharma R, Khristov V, Rising A, Jha BS, Dejene R, Hotaling N, Li Y, Stoddard J, Stankewicz C, Wan Q, Zhang C, Campos MM, Miyagishima KJ, McGaughey D, Villasmil R, Mattapallil M, Stanzel B, Qian H, Wong W, Chase L, Charles S, McGill T, Miller S, Maminishkis A, Amaral J, Bharti K. Clinical-grade stem cell-derived retinal pigment epithelium patch rescues retinal degeneration in rodents and pigs. *Sci Transl Med* 2019 Jan 16;11(475):eaat5580.. [PubMed: 30651323]
- Sharma R, Bose D, Maminishkis A, Bharti K. Retinal Pigment Epithelium Replacement Therapy for Age-Related Macular Degeneration: Are We There Yet? *Annu Rev Pharmacol Toxicol* 2020 Jan 6;60:553–572. [PubMed: 31914900]
- Sharma R, George A, Nimmagadda M, Ortolan D, Karla BS, Qureshy Z, Bose D, Dejene R, Liang G, Wan Q, Chang J, Jha BS, Memon O, Miyagishima KJ, Rising A, Lal M, Hanson E, King R, Campos MM, Ferrer M, Amaral J, McGaughey D, Bharti K. Epithelial phenotype restoring drugs suppress macular degeneration phenotypes in an iPSC model. *Nat Commun* 2021 Dec 15;12(1):7293. [PubMed: 34911940]
- Sonoda S, Spee C, Barron E, Ryan SJ, Kannan R, Hinton DR. A protocol for the culture and differentiation of highly polarized human retinal pigment epithelial cells. *Nat Protoc* 2009;4(5):662–73. [PubMed: 19373231]
- Sorkio A, Hongisto H, Kaarniranta K, Uusitalo H, Juuti-Uusitalo K, Skottman H. Structure and barrier properties of human embryonic stem cell-derived retinal pigment epithelial cells are affected by extracellular matrix protein coating. *Tissue Eng Part A* 2014 Feb;20(3–4):622–34. [PubMed: 24044751]
- Srinivasan B, Kolli AR, Esch MB, Abaci HE, Shuler ML, Hickman JJ. TEER measurement techniques for in vitro barrier model systems. *J Lab Autom* 2015 Apr;20(2):107–26. [PubMed: 25586998]
- Storti F, Klee K, Todorova V, Steiner R, Othman A, van der Velde-Visser S, Samardzija M, Meneau I, Barben M, Karademir D, Pauzuolyte V, Boye SL, Blaser F, Ullmer C, Dunaief JL, Hornemann T, Rohrer L, den Hollander A, von Eckardstein A, Fingerle J, Maugeais C, Grimm C. Impaired ABCA1/ABCG1-mediated lipid efflux in the mouse retinal pigment epithelium (RPE) leads to retinal degeneration. *Elife* 2019 Mar 13;8:e45100. [PubMed: 30864945]
- Strunnikova NV, Maminishkis A, Barb JJ, Wang F, Zhi C, Sergeev Y, Chen W, Edwards AO, Stambolian D, Abecasis G, Swaroop A, Munson PJ, Miller SS. Transcriptome analysis and molecular signature of human retinal pigment epithelium. *Hum Mol Genet* 2010 Jun 15;19(12):2468–86. [PubMed: 20360305]
- Sugita S, Makabe K, Fujii S, Takahashi M. Detection of Complement Activators in Immune Attack Eyes After iPS-Derived Retinal Pigment Epithelial Cell Transplantation. *Invest Ophthalmol Vis Sci* 2018 Aug 1;59(10):4198–4209. [PubMed: 30128491]

- Sullivan PM, Mezdour H, Quarfordt SH, Maeda N. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. *J Clin Invest* 1998 Jul 1;102(1):130–5. [PubMed: 9649566]
- Suzuki M, Betsuyaku T, Ito Y, Nagai K, Nasuhara Y, Kaga K, Kondo S, Nishimura M. Down-regulated NF-E2-related factor 2 in pulmonary macrophages of aged smokers and patients with chronic obstructive pulmonary disease. *Am J Respir Cell Mol Biol* 2008 Dec;39(6):673–82. [PubMed: 18566336]
- Swaroop A, Chew EY, Rickman CB, Abecasis GR. Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration. *Annu Rev Genomics Hum Genet* 2009;10:19–43. [PubMed: 19405847]
- Tan LX, Toops KA, Lakkaraju A. Protective responses to sublytic complement in the retinal pigment epithelium. *Proc Natl Acad Sci U S A* 2016 Aug 2;113(31):8789–94. d [PubMed: 27432952]
- Toops KA, Tan LX, Lakkaraju A. A detailed three-step protocol for live imaging of intracellular traffic in polarized primary porcine RPE monolayers. *Exp Eye Res* 2014 Jul;124:74–85. [PubMed: 24861273]
- Toops KA, Tan LX, Jiang Z, Radu RA, Lakkaraju A. Cholesterol-mediated activation of acid sphingomyelinase disrupts autophagy in the retinal pigment epithelium. *Mol Biol Cell* 2015 Jan 1;26(1):1–14. [PubMed: 25378587]
- Trivedi D, Colin E, Louie CM, Williams DS. Live-cell imaging evidence for the ciliary transport of rod photoreceptor opsin by heterotrimeric kinesin-2. *J Neurosci* 2012 Aug 1;32(31):10587–93. [PubMed: 22855808]
- Tsai YT, Li Y, Ryu J, Su PY, Cheng CH, Wu WH, Li YS, Quinn PMJ, Leong KW, Tsang SH. Impaired cholesterol efflux in retinal pigment epithelium of individuals with juvenile macular degeneration. *Am J Hum Genet* 2021 May 6;108(5):903–918. [PubMed: 33909993]
- Tseng WA, Thein T, Kinnunen K, Lashkari K, Gregory MS, D'Amore PA, Ksander BR. NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: implications for age-related macular degeneration. *Invest Ophthalmol Vis Sci* 2013 Jan 7;54(1):110–20. [PubMed: 23221073]
- Valapala M, Wilson C, Hose S, Bhutto IA, Grebe R, Dong A, Greenbaum S, Gu L, Sengupta S, Cano M, Hackett S, Xu G, Luty GA, Dong L, Sergeev Y, Handa JT, Campochiaro P, Wawrousek E, Zigler JS Jr, Sinha D. Lysosomal-mediated waste clearance in retinal pigment epithelial cells is regulated by CRYBA1/BA3/A1-crystallin via V-ATPase-MTORC1 signaling. *Autophagy* 2014 Mar;10(3):480–96. [PubMed: 24468901]
- Williams JA, Zhao K, Jin S, Ding WX. New methods for monitoring mitochondrial biogenesis and mitophagy in vitro and in vivo. *Exp Biol Med* 2017 Apr;242(8):781–787.
- Wright C, Mazzucco AE, Becker SM, Sieving PA, Tumminia SJ. NEI-Supported Age-Related Macular Degeneration Research: Past, Present, and Future. *Transl Vis Sci Technol* 2020 Jun 30;9(7):49.
- van Leeuwen EM, Emri E, Merle BMJ, Colijn JM, Kersten E, Cougnard-Gregoire A, Dammeier S, Meester-Smoor M, Pool FM, de Jong EK, Delcourt C, Rodrigez-Bocanegra E, Biarnés M, Luthert PJ, Ueffing M, Klaver CCW, Nogoceke E, den Hollander AI, Lengyel I. A new perspective on lipid research in age-related macular degeneration. *Prog Retin Eye Res* 2018 Nov;67:56–86. [PubMed: 29729972]
- Wang J, Zibetti C, Shang P, Sripathi SR, Zhang P, Cano M, Hoang T, Xia S, Ji H, Merbs SL, Zack DJ, Handa JT, Sinha D, Blackshaw S, Qian J. ATAC-Seq analysis reveals a widespread decrease of chromatin accessibility in age-related macular degeneration. *Nat Commun* 2018 Apr 10;9(1):1364. [PubMed: 29636475]
- Xu YT, Wang Y, Chen P, Xu HF. Age-related maculopathy susceptibility 2 participates in the phagocytosis functions of the retinal pigment epithelium. *Int J Ophthalmol* 2012;5(2):125–32. [PubMed: 22762035]
- Yang J, Li Y, Chan L, Tsai YT, Wu WH, Nguyen HV, Hsu CW, Li X, Brown LM, Egli D, Sparrow JR, Tsang SH. Validation of genome-wide association study (GWAS)-identified disease risk alleles with patient-specific stem cell lines. *Hum Mol Genet* 2014 Jul 1;23(13):3445–55. [PubMed: 24497574]

- Yang J, Yang K, Meng X, Liu P, Fu Y, Wang Y. Silenced SNHG1 Inhibited Epithelial-Mesenchymal Transition and Inflammatory Response of ARPE-19 Cells Induced by High Glucose. *J Inflamm Res* 2021 Apr 20;14:1563–1573. [PubMed: 33907437]
- Zhang M, Jiang N, Chu Y, Postnikova O, Varghese R, Horvath A, Cheema AK, Golestaneh N. Dysregulated metabolic pathways in age-related macular degeneration. *Sci Rep* 2020 Feb 12;10(1):2464. [PubMed: 32051464]
- Zigler JS Jr, Sinha D. β A3/A1-crystallin: more than a lens protein. *Prog Retin Eye Res* 2015 Jan;44:62–85. [PubMed: 25461968]
- Zweifel SA, Spaide RF, Curcio CA, Malek G, Imamura Y. Reticular pseudodrusen are subretinal drusenoid deposits. *Ophthalmology* 2010 Feb;117(2):303–12.e1. [PubMed: 19815280]

Highlights:

- *In vitro* models of the RPE provide a powerful tool to study RPE biology and AMD pathogenesis
- Key hallmarks of AMD pathophysiology have been replicated in several *in vitro* models
- Primary RPE and RPE cell lines are easily accessible and useful in biochemical and cell biology studies
- iPSC-derived RPE have been validated to present native-RPE like features and can provide patient-specific models
- Organ-on-chips and 3D organoids provide physiologically relevant models combining RPE with choriocapillaris and/or retinal photoreceptors

Table 1

Properties of RPE cell cultures from different source.

	ARPE19 ^a	Mouse primary RPE ^b	Pig primary RPE ^c	Human primary RPE (fetal origin) ^d	Human primary RPE (adult origin) ^e	iPSC-RPE ^f
Accessibility	High	Moderate	Moderate	Low	Low	High
Culture methods	Easy	Intermediate	Intermediate	Intermediate	Difficult	Difficult, variable
Time to full differentiation	Short-Medium (2-4 weeks)	Short-Medium (<1-4 weeks)	Short (2 weeks)	Long (8 weeks)	Medium (4 weeks)	Long (10 weeks)
Cost	Low	Moderate	Low-Moderate	High	High	High
Expandability	High	Low	Low	Moderate	Low	Moderate (but can differentiate a new batch)
Cell phenotype - Hexagonality - Pigmentation - Junctional resistance - Polarity						
	Moderate	Moderate	High	High	Moderate	High
	Low	Moderate	Moderate-High	High	Moderate	Moderate-High
	Low	Moderate	High	High	Low	High
Developmental stage	Moderate	Moderate	High	High	Moderate	High
	N/A	High (fully differentiated)	High (fully differentiated)	Moderate	High	High (similar to adult RPE)
Connection to AMD genetics	Possible	Possible	Possible	Possible	Extensive	Extensive
Ability to model AMD pathology	Moderate	Moderate	Moderate	Moderate	High	High
Genetic manipulation	Possible	Possible	Possible	None-possible	None	Extensive
Usability - Biochemistry - Cell biology - High throughput screens						
	High	High	High	Moderate	Low	High
	High	Moderate	High	Moderate	High	High
	High	Moderate	Moderate	Low	Low	High

Scales used: (1) high, moderate, low; (2) easy, intermediate, difficult; (3) none, possible, extensive; (4) short, medium, long

^aDavis et al., 1995; Dunn et al., 1996; Hazim et al., 2019

^bGibbs et al., 2003; Gibbs and Williams, 2003; Fernandez-Godino et al., 2016; Shang et al. 2021

^cToops et al., 2014; Georgiannakis et al., 2015; Klingeborn et al., 2017

^dHu and Bok 2001; Mammishkis et al., 2006; Sonoda et al., 2009

^e Fernandes et al., 2018
^f May-Simera et al., 2018; Sharma et al., 2019; Sharma et al., 2020

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript